Protein hydrolysis targeting viruses, their live vaccines, their preparation methods and uses

By introducing conditionally cleavable proteolytic targeting molecules into the influenza virus genome and utilizing the ubiquitin-proteasome system for efficient replication in specific cell lines, the problems of antigenic variation in chicken embryos and unstable immune efficacy in humans have been solved, achieving safe and efficient live vaccine preparation.

CN112175914BActive Publication Date: 2026-11-10司龙龙 +2
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202010635620.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-05
Filing Date
2020-07-03
Publication Date
2026-11-10
Estimated Expiration
2040-07-03

AI Technical Summary

Technical Problem

Existing influenza virus vaccines are prone to antigenic mutation when passaged in chicken embryos, and vaccines cultured in mammalian cells have unstable immune effects in humans, posing safety and production efficiency issues.

Method used

By introducing conditionally cleavable proteolytic targeting molecules into the influenza virus genome, utilizing the ubiquitin-proteasome system to efficiently replicate in specific cell lines, and losing the ability to replicate in humans, and by selectively cleaving the linker strand to avoid viral protein degradation, a highly safe live vaccine can be prepared.

Benefits of technology

This enabled the efficient production of influenza virus in specific cell lines, enhanced the immunogenicity and safety of the vaccine, prevented replication and reproduction in the human body, and improved the safety and production efficiency of the vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112175914B_ABST
    Figure CN112175914B_ABST
Patent Text Reader

Abstract

This invention provides a protein-targeting virus, wherein the virus contains one or more protein-targeting molecules that can be recognized by the ubiquitin-proteasome system at one or more sites on one or more different proteins; and the viral protein and the protein-targeting molecules are linked by zero or more linker strands; wherein the linker strands can be selectively cleaved. This invention also provides a method for preparing the protein-targeting virus. Specifically, this invention provides a protein-targeting influenza virus and its preparation method. The protein-targeting virus and its preparation method provided by this invention can be widely used in live vaccines, attenuated vaccines, inactivated vaccines, and safety models of virulent strains. Compared with existing technologies, the protein-targeting virus and its preparation method provided by this invention are used to design vaccines with different degrees of inactivation, have safety and controllability, and these vaccines have good immunogenicity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology. Specifically, this invention relates to a protein hydrolysis-targeting virus and its uses. This invention also provides a method for preparing the virus. Background Technology

[0002] Influenza is an acute respiratory infectious disease caused by the influenza virus, which can seasonally infect birds, mammals, and humans. Influenza viruses are classified into three types: A, B, and C, with type A (also known as influenza A virus) outbreaks being the most frequent. Influenza A virus belongs to the Orthomyxoviridae family, and its genome consists of eight independent single-stranded RNA segments encoding ten proteins: hemagglutinin (HA); matrix protein (M), which is divided into M1 and M2; neuraminidase (NA); nucleocapsid protein (NP); non-structural protein (NS), including NS1 and NEP; and three polymerases: PB1, PB2, and PA. Each protein has an important biological function for the influenza virus. Influenza A virus is classified into different subtypes based on the antigenicity of its main surface antigens, HA and NA. Currently, 18 subtypes of HA protein and 11 subtypes of NA protein have been identified. Large-scale epidemics of influenza A virus can cause extremely high morbidity and mortality rates, seriously threatening human health (WHO 2003; Coleman 2007). Influenza A viruses caused three major influenza pandemics in the 20th century: H1N1 in 1918, H2N2 in 1957, and H3N2 in 1968, resulting in approximately 50 million deaths (Kilbourne 2006; Taubenberger, Hultin et al. 2007). The 2009 influenza A pandemic, also caused by the H1N1 virus (Dawood, Jain et al. 2009; Zimmer and Burke 2009), spread rapidly, drawing global attention. It is estimated that an average of 300,000 to 500,000 people worldwide die from influenza each year (Fiore, Shay et al. 2007).

[0003] Since the discovery of influenza, scientists have been dedicated to controlling the influenza virus. Vaccination is currently the most effective means of preventing and controlling the spread of influenza. In the late 1930s, influenza vaccines began to be used in humans. Current influenza vaccines are classified into the following types: inactivated virus vaccines, live attenuated virus vaccines, DNA vaccines, subunit vaccines, recombinant viral vector vaccines, and virus-like particle vaccines.

[0004] Currently used inactivated influenza vaccines are trivalent vaccines, including vaccines against H1N1, H3N2, and influenza B viruses. Years of clinical application have shown that inactivated influenza vaccines have good immunogenicity and safety, stimulating the body to produce corresponding antibodies after vaccination. However, a drawback is that they cannot stimulate the production of secretory immunoglobulin (sIgA). Furthermore, influenza viruses undergo antigenic variation during passage in chicken embryos, and most chickens carry multiple viruses, meaning vaccines may be contaminated by these viruses. Since newly circulating antigenic variants must be able to replicate efficiently in chicken embryos to produce large quantities of vaccines, the immunogenicity of the wild-type virus used in vaccine preparation is altered or reduced to some extent as it grows in eggs. If the produced vaccine strain does not match the currently circulating strain, it will lose its protective effect. In recent years, a significant advancement has been the use of mammalian cells instead of chicken embryo culture. Mammalian cells, primarily MDCK cells and Vero cells, have advantages such as no exogenous factor contamination, ease of large-scale production, and antigenic stability. Influenza vaccines cultured in mammalian cells have good immunogenicity, mild adverse reactions after vaccination, and are relatively safe. The research phase has yielded excellent experimental results. However, some problems remain unresolved, and its clinical use has not yet been observed.

[0005] Live attenuated vaccines mainly include five types: temperature-sensitive vaccines, reassortant vaccines, cold-adapted live attenuated influenza vaccines, reverse genetics vaccines, and replication-deficient influenza vaccines. The cold-adapted live attenuated influenza vaccine has been successfully developed. This vaccine uses an influenza virus strain with reduced virulence that can grow at its optimal temperature. This virus can only replicate at around 25°C and cannot be passaged at 37°C; therefore, its infection is limited to the upper respiratory tract, and there are no obvious clinical symptoms of influenza. It is produced by genetic recombination of a weakened strain with the currently circulating strain, resulting in a recombinant virus carrying fragments of the weakened strain and the HA and NA genes of the circulating strain. Multiple studies have confirmed that the cold-adapted strain has excellent biological stability. The seroconversion rate of antibodies after immunization with both the weakened and inactivated influenza vaccines is 50%–70%, effectively controlling influenza epidemics. The cold-adapted live attenuated influenza vaccine is already in use in Russia and will soon be approved for use in the United States. It has certain advantages over inactivated vaccines in terms of administration route and immunization efficacy, such as being able to be administered via nasal spray or intravenous drip. Cold-adapted live attenuated vaccines replicate in the upper respiratory tract, inducing mucosal sIgA and systemic humoral and cellular immune responses, producing broader and longer-lasting protection than inactivated vaccines. However, cold-adapted live attenuated vaccines can undergo gene reassortment with other influenza viruses to obtain virulent reassortant strains, and interference may occur in bivalent or trivalent cold-adapted live attenuated vaccines.

[0006] An ideal vaccine should meet the following conditions: ① strong immunogenicity, ② low toxicity, ③ genetic stability, and ④ rapid acquisition of antigenicity consistent with the circulating strain during epidemic periods. Given the advantages of live vaccines over inactivated vaccines and safety considerations for live vaccines, the use of mammalian cells to produce novel live influenza virus vaccines with controllable replication, genetic stability, and safety and efficacy will improve vaccine safety and effectiveness and promote the rapid development of influenza vaccines.

[0007] ubiquitin-proteasome system

[0008] Protein degradation is crucial for maintaining normal cellular functions, such as proliferation, differentiation, and death. In eukaryotic cells, protein degradation primarily occurs via the lysosomal pathway, specialized organelle hydrolytic systems, cell membrane surface hydrolytic systems, the caspase protease system, and the highly conserved ubiquitin-proteasome pathway (UPP). The ubiquitin-proteasome pathway is an ATP-dependent, non-lysosomal protein degradation pathway in the cytoplasm and nucleus. It efficiently and selectively degrades proteins produced by cells under stress and non-stress conditions, especially short-lived functional proteins, oncogene products, and denatured or allosteric proteins. It can also degrade intracellular structural proteins under stress. The discovery of this protein hydrolysis pathway is considered a turning point in research on the cell cycle and cellular deterioration, and it is a vital regulator of cellular function.

[0009] The ubiquitin-proteasome system consists of ubiquitin, ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), ubiquitin-protein ligases (E3), and the proteasome. Ubiquitin is a highly conserved small protein composed of 76 amino acids with a molecular weight of 8.45 kJ. It is widely distributed from the cell nucleus to the cytoplasm, from germ cells to various somatic cells, and is highly expressed in proliferating tumor cells and embryonic cells. With the assistance of ubiquitin ligases, the glycine carboxyl group at the C-terminus of ubiquitin binds to the α or ε amino group of the target protein to form a polyubiquitin chain, facilitating the recognition and hydrolysis of the target protein by the proteolytic enzyme complex. Ubiquitin-activating enzymes (E1) catalyze the binding of ubiquitin to the protein substrate. Once the ubiquitin pathway is initiated, with the participation of ATP, the C-terminus of the glycine residue of ubiquitin is linked to the cysteine ​​residue (Cys) at the activation site of ubiquitin-conjugating enzyme (E2), thereby activating ubiquitin. After ubiquitin activation, the activated ubiquitin is transferred to the cysteine ​​residue at the activation site of ubiquitin-conjugating enzyme (E2). Ubiquitin ligase (E3) plays a crucial role in determining the selectivity of ubiquitin-mediated substrate protein degradation. E3 has an affinity for the enzyme substrate and needs to be linked to E2 to transfer ubiquitin from E2 to the target protein. After ubiquitin binds to the enzyme substrate, a polyubiquitin chain is typically formed. In this chain, the C-terminus of each ubiquitin monomer is linked to a specific lysine residue of the preceding ubiquitin. The proteasome is a key enzyme catalyzing the degradation of ubiquitin-substrate conjugates, including the 20S and 26S proteasomes. The α subunit of the 20S proteasome is primarily used for substrate recognition, while the β subunit is primarily used for substrate degradation. The role of the 26S proteasome may be related to the production of free peptides, free ubiquitin, or reusable ubiquitin. Therefore, the ubiquitin-proteasome system consists of two consecutive steps: (1) covalent binding of ubiquitin molecules to target proteins; and (2) degradation of polyubiquitinated proteins by the 26S proteasome complex, while ubiquitin is reactivated. This process requires the assistance of three enzymes, E1, E2, and E3, and it permeates the entire cell membrane system, including the cell membrane, endoplasmic reticulum, and nuclear membrane. The ubiquitin-proteasome pathway is an important protein regulatory system in eukaryotic cells, participating in the regulation of various cellular physiological processes such as cell cycle progression, cell proliferation and differentiation, and signal transduction. Therefore, intracellular protein ubiquitination degradation is an important post-transcriptional modification of proteins.

[0010] In short, cells in a living organism constantly strive to maintain appropriate protein levels, generating and degrading thousands of proteins every moment. A key factor in maintaining protein homeostasis is a small protein called ubiquitin. When ubiquitin is linked to a protein, it causes that protein to be transported to the proteasome for degradation. Utilizing this principle, researchers have developed protein degraders based on proteolysis-targeting chimeras (PROTACs). This involves designing a small molecule with two active terminals: one that binds to a targeted protein, and the other that binds to a protein called E3 ubiquitin ligase. This bifunctional molecule forces ubiquitin to bind to the target protein, transporting it to the cell's waste disposal system. After the protein is degraded, it can continue to target other proteins, rapidly reducing the levels of unwanted proteins.

[0011] However, there are currently no reports of this technology being used for virus modification. Summary of the Invention

[0012] To address the shortcomings of existing technologies, this invention provides a protein-hydrolyzing targeted virus comprising molecules and a linker that can be recognized by the ubiquitin-proteasome system. This invention also provides a method for preparing the virus and its uses.

[0013] In this application, the term "proteolysis-targeting molecules" refers to various molecules, including polypeptides, amino acid sequences, proteins, or other molecules, that can be recognized by the ubiquitin-proteasome system. The applicant has discovered that by introducing the encoding nucleotide sequence of the proteolysis-targeting molecule into the genome of a virus, the proteolysis-targeting molecule can replicate along with the viral genome and can be fused and expressed in viral proteins during viral protein translation, thereby obtaining a virus specifically modified by the proteolysis-targeting molecule, i.e., a proteolysis-targeting chimeric virus (PROTAC virus).

[0014] Because the ubiquitin-proteasome system is widely present in host cells, to prevent the degradation of PROTAC viruses by the intracellular ubiquitin-proteasome system during preparation, which would reduce production efficiency, the inventors introduced a selectively cleavable linker between the viral protein and the proteolytic target molecule. This linker can be cleaved in specific artificially modified cell lines, thereby separating the viral protein from the proteolytic target molecule. The viral protein is retained and is not degraded by the ubiquitin-proteasome system, allowing PROTAC viruses to replicate efficiently and be produced in large quantities in these specific artificially modified cell lines. In normal cells, the ubiquitin-proteasome system recognizes the proteolytic target molecule fused to the viral protein, thereby degrading the viral protein and weakening or even completely eliminating the virus's replication ability. Therefore, PROTAC viruses have high safety. Furthermore, PROTAC viruses can be further modified, for example, by introducing immunostimulants into specific regions or amino acids of the viral protein, resulting in viruses with improved performance and enhanced immunogenicity.

[0015] Another objective of this invention is to introduce the coding nucleotide sequence of a conditionally cleavable proteolytic target molecule into the influenza virus genome, enabling the influenza virus to replicate only in a specific virus production system capable of cleaving or inactivating the proteolytic target molecule. Utilizing the influenza virus's dependence on this specific virus production system, large-scale production of the influenza virus can be achieved within this system. Because the ubiquitin-proteasome pathway exists in normal cells of humans and animals, it can recognize the proteolytic target molecule expressed fused with viral proteins, thereby degrading the viral proteins. Therefore, the prepared influenza virus cannot replicate in animals or humans, increasing the virus's safety and making it a truly live influenza vaccine. Furthermore, the ubiquitin-proteasome system in animals and humans can recognize a variety of proteolytic target molecules, thus allowing the introduction of different types and quantities of proteolytic target molecules into viral proteins. Additionally, there are various types of linkers that can be selectively cleaved, enabling the introduction of different types and quantities of linkers to achieve selective cleavage of proteolytic target molecules. These different types and quantities of proteolytic target molecules and linkers can be combined arbitrarily, ensuring the preparation of viral vaccines with varying replication efficiencies and attenuation levels. This is crucial for the production efficiency and immunogenicity of influenza virus vaccines.

[0016] The principle of this protein hydrolysis-targeting virus is as follows: (1) The protein hydrolysis-targeting molecule introduced to a specific site of the viral protein can be recognized by the ubiquitin-proteasome system in normal host cells, thereby degrading and inactivating the relevant viral protein; (2) The protein hydrolysis-targeting molecule introduced to a specific site of the viral protein can be inhibited in a specific virus production system, or selectively cleaved through the linker chain, thus separating from the viral protein, thereby avoiding or reducing the degradation of the viral protein by the ubiquitin-proteasome pathway; (3) The protein hydrolysis-targeting molecule introduced to a specific site of the viral protein cannot be inhibited in normal host cells, or the linker chain connecting the protein hydrolysis-targeting molecule to the viral protein cannot be cleaved in normal host cells. Therefore, the prepared virus can be recognized and degraded by the ubiquitin-proteasome pathway in host cells such as animals and humans, and its replication ability is reduced or even completely lost, increasing the safety of the virus.

[0017] On one hand, the present invention provides a proteolytic targeting virus, wherein the virus contains one or more proteolytic targeting molecules that can be recognized by the ubiquitin-proteasome system at one or more different viral protein sites; and the viral protein and the proteolytic targeting molecules are connected by zero or one or more linker strands; wherein the linker strands can be selectively cleaved.

[0018] Preferably, the site is the C-terminus and / or N-terminus of the protein, that is, the C-terminus and / or N-terminus of the viral gene fragment, or any other arbitrary site.

[0019] The protein hydrolysis-targeting virus according to the present invention. The plurality of protein hydrolysis-targeting molecules may be the same protein hydrolysis-targeting molecule or a combination of different protein hydrolysis-targeting molecules; the plurality of linking strands may be the same linking strand or a combination of different linking strands.

[0020] Preferably, the protein hydrolysis targeting molecule is selected from the amino acid sequences shown in any one of SEQ ID NO:1-110:

[0021]

[0022]

[0023]

[0024]

[0025]

[0026] Preferably, the linker chain is selected from any selectively cleavable molecule, preferably an amino acid sequence, such as molecules selectively cleavable by Tobacco etch virus protease (TEVp); or thrombin-sensitive cleavable molecules (with LVPR cleavage site). * GS, such as SEQ ID NO:111LEAGCKNFFPRSFTSCGSLE); molecules that can be cleaved by coagulation factor Xa (cleavage site is IDGR). * Molecules that can be cleaved by enterokinase (cleavage site is DDDDK) * Molecules that can be cleaved by 3C proteases (cleavage site is ETLFQ) * GP); molecules and sequences that can be cleaved by SUMO protease; molecules that can be cleaved by bacterial gelatinase (such as GPLGV); self-cleaving linkers, preferably, the self-cleaving linkers are selected from 2A short peptides, such as P2A derived from porcine teschovirus-1, E2A derived from equine rhinitis A virus, F2A derived from foot and mouth disease virus, self-cleaving T2A, etc.

[0027] More preferably, the connecting chain is any sequence EX that can be recognized and cut by TEVp. aa -X aa -YX aa -Q-(G / S / M) (the cleavage occurs between Q and G, or between Q and S, or between Q and M; Xaa indicates that it can be any amino acid; in this document, this sequence is called the Tobacco etch virus protease cleavage sequence, and the cleavage site is called the Tobacco etch virus protease cleavage site, TEVcs), specifically selected from the amino acid sequences shown in any one of SEQ ID NO:112-137.

[0028]

[0029]

[0030] Preferably, a flexible linker is further included between the protein hydrolysis targeting molecule and the linker chain;

[0031] More preferably, the protein hydrolysis targeting molecule, the linker chain, and the flexible connector have the following connection method:

[0032] Flexible connector - connecting chain - flexible connector - protein hydrolysis targeting molecule;

[0033] More preferably, the flexible connector-connector-flexible connector-protein hydrolysis targeting molecule is selected from the amino acid sequences shown in any one of SEQ ID NO:138-149, 167 and 168.

[0034]

[0035]

[0036] Preferably, the virus is selected from influenza virus, HIV, hand-foot-and-mouth disease virus, Coxsackie virus, hepatitis C virus (HCV), hepatitis B virus (HBV), hepatitis A virus, hepatitis D virus, hepatitis E virus, Epstein-Barr virus (EBV), human papillomavirus (HPV), herpes simplex virus (HSV), cytomegalovirus, varicella-zoster virus, vesicular stomatitis virus, respiratory syncytial virus (RSV), dengue virus, Ebola virus, Marburg virus, Zika virus, SARS, Middle East Respiratory Syndrome virus (MERS), rotavirus, rabies virus, measles virus, adenovirus, etc. Poliovirus, echovirus, Japanese encephalitis virus, tick-borne encephalitis virus, Hantavirus, novel enterovirus, rubella virus, mumps virus, parainfluenza virus, porcine reproductive and respiratory syndrome virus, classical swine fever virus, foot-and-mouth disease virus, parvovirus, prions, smallpox virus, tobacco mosaic virus, adeno-associated virus, bacteriophage, herpesvirus, West Nile virus, norovirus, human bocavirus, coronavirus, and SARS-CoV-2; more preferably, the virus is influenza virus or SARS-CoV-2.

[0037] Preferably, the virus is a modified virus, which is modified or contains a combination of several insertion modifications.

[0038] According to a specific embodiment of the present invention, a proteolytic-targeting influenza virus (PROTAC influenza virus) is provided, wherein the influenza virus contains one or more proteolytic-targeting molecules that can be recognized by the ubiquitin-proteasome system at one or more different viral protein sites; and the viral protein and the proteolytic-targeting molecules are linked by zero or more linker strands; wherein the linker strands are EX aa -X aa -YX aa -Q-(G / S) can be specifically recognized and cleaved by Tobacco etch virus protease (TEVp).

[0039] Preferably, one or more of the PA, PB1, PB2, NP, HA, NA, M1, M2, NS1, and NEP proteins of the influenza virus contain a proteolytic targeting molecule and a linker strand; that is, one or more of the PA, PB1, PB2, NP, HA, NA, M1, M2, NS1, and NEP gene fragments of the influenza virus genome contain nucleotide sequences encoding the proteolytic targeting molecule and the linker strand, wherein the proteolytic targeting molecule and the linker strand are site-specifically modified to the corresponding sites of one or more of the PA, PB1, PB2, NP, HA, NA, M1, M2, NS1, and NEP proteins of the influenza virus.

[0040] Preferably, both PA and PB2 of the influenza virus contain one or more proteolytic targeting molecules and linker chains;

[0041] Both the PA and PB1 proteins of influenza viruses contain one or more proteolytic targeting molecules and linker chains.

[0042] Both the PB2 and PB1 proteins of influenza virus contain one or more proteolytic targeting molecules and linker chains.

[0043] The PA, PB2, and PB1 proteins of influenza viruses each contain one or more proteolytic targeting molecules and linker chains.

[0044] The PA, PB2, PB1, and M1 proteins of influenza viruses each contain one or more proteolytic targeting molecules and linker chains.

[0045] The PA, PB2, PB1, M1, and NP proteins of influenza viruses each contain one or more proteolytic targeting molecules and linker chains.

[0046] The PB2, PB1, and M1 proteins of influenza virus each contain one or more proteolytic targeting molecules and linker chains.

[0047] Both the PA and M1 proteins of influenza viruses contain one or more proteolytic targeting molecules and linker chains.

[0048] Both the PB1 and M1 proteins of influenza virus contain one or more proteolytic targeting molecules and linker strands.

[0049] Both the PB2 and M1 proteins of influenza viruses contain one or more proteolytic targeting molecules and linker chains.

[0050] The PB2, PB1, M1, and NS1 proteins of influenza viruses each contain one or more proteolytic targeting molecules and linker chains.

[0051] The PB2, PB1, M1, and NEP proteins of influenza viruses all contain one or more proteolytic targeting molecules and linker chains; or

[0052] Both the NS1 and NEP proteins of influenza viruses contain one or more proteolytic targeting molecules and linker chains.

[0053] Preferably, the proteolytic-targeting virus is a proteolytic-targeting coronavirus, wherein the coronavirus contains one or more proteolytic-targeting molecules that can be recognized by the ubiquitin-proteasome system at one or more different sites on its viral proteins; and the viral proteins and the proteolytic-targeting molecules are linked by zero or more linker strands; wherein the linker strands are EX aa -X aa -YX aa -Q-(G / S / M), which can be specifically recognized and cleaved by tobacco plaque virus protease;

[0054] Preferably, the virus is the novel coronavirus SARS-CoV-2;

[0055] More preferably, in the spike protein (S) protein, envelope glycoprotein (E) glycoprotein, membrane glycoprotein (M) glycoprotein, nucleocapsid protein (N) protein, nonstructural protein 1 (nsp1), nonstructural protein 2, nonstructural protein 3, nonstructural protein 4, nonstructural protein 5, nonstructural protein 6, nonstructural protein 7, nonstructural protein 8, nonstructural protein 9, nonstructural protein 10, nonstructural protein 11, nonstructural protein 12, nonstructural protein 13, nonstructural protein 14, nonstructural protein 15, nonstructural protein 16, 3a protein, 3b protein, 6 protein, 7a protein, 7b protein, 8a protein, 8b protein, 9b protein, 3C-like proteinase, leader protein of the coronavirus. One or more of the following proteins contain one or more protein hydrolysis target molecules and linker strands: protein, 2'-O-ribosemethyltransferase, endoRNAse, 3'-to-5' exonuclease, helicase, RNA-dependent RNA polymerase, orf1a polyprotein, ORF10 protein, ORF8 protein, ORF7a protein, ORF6 protein, and ORF3a protein.

[0056] Preferably, the proteolytic-targeting virus is a proteolytic-targeting HIV virus, wherein the HIV virus contains one or more proteolytic-targeting molecules that can be recognized by the ubiquitin-proteasome system at one or more different sites on its viral proteins; and the viral proteins and the proteolytic-targeting molecules are linked by zero or more linker strands; wherein the linker strand is EX. aa -X aa -YX aa -Q-(G / S / M), which can be specifically recognized and cleaved by tobacco plaque virus protease;

[0057] Preferably, the virus is HIV.

[0058] Preferably, the following components are present in the HIV virus: Gag polyprotein, pol polyprotein, gp160, HIV trans-activator of transcription (Tat), regulator of expression of virion proteins (Rev), negative factor (Nef), lentivirus protein R (Vpr), viral infectivity factor (Vif), virus protein U (Vpu), matrix protein (MA, p17), capsid protein (CA, p24), spacerpeptide 1 (SP1, p2), nucleocapsid protein (NC, p7), spacerpeptide 2 (SP2, p1), p6, reverse transcriptase (RT), and ribonuclease H (RNase). One or more of the following proteins contain one or more proteolytic target molecules and linker chains: H), integrase (IN), HIV protease (PR), gp120, and gp41.

[0059] In one embodiment of the present invention, using reverse genetics technology, the inventors can replace any gene of an existing influenza virus model with a gene of another subtype or strain, or replace an existing influenza virus model with another subtype or strain, thereby preparing influenza viruses of other subtypes or strains. This method can be applied to influenza viruses of any subtype or strain, and the prepared virus can replicate in large quantities in cell lines in which proteolytic target molecules can be selectively cleaved, while in normal host cells it will be recognized and degraded by the ubiquitin-protease system. Furthermore, this method can be applied to other subtypes or strains, including H1N1, H1N2, H1N3, H1N8, H1N9, H2N2, H2N3, H2N8, H3N1, H3N2, H3N8, H4N2, H4N4, H4N6, H4N8, H5N1, H5N2, H5N3, H5N6, H5N8, H5N9, H6N1, H6N2, H6N4, H6N5, H6N6, H6N8, H7N1, H7 The influenza viruses produced include H2, H7N3, H7N7, H7N8, H7N9, H8N4, H9N1, H9N2, H9N5, H9N8, H10N3, H10N4, H10N7, H10N8, H10N9, H11N2, H11N6, H11N9, H12N1, H12N3, H12N5, H13N6, H13N8, H14N5, H15N2, H15N8, H16N3, H17N10, and H18N11. Furthermore, using reverse genetics, multivalent influenza viruses can be prepared, such as those containing H1N1, H3N2, and influenza B virus surface antigens. More importantly, the resulting mutant virulent and multivalent viruses exhibit very high safety and efficacy.

[0060] The present invention also provides a nucleic acid molecule encoding the protein hydrolysis targeting virus.

[0061] The present invention also provides a nucleic acid vector for expressing the protein hydrolysis-targeting virus.

[0062] On the other hand, the present invention provides a method for preparing a protein hydrolysis-targeted virus, the method comprising the following steps:

[0063] 1) Cell line construction: Construct a cell line that can stably express a protease that selectively cleaves the linker strand of a virus that targets protein hydrolysis;

[0064] Preferably, the cell line is a mammalian cell line;

[0065] More preferably, the cell lines are selected from CHO cells, Vero cells, MDCK.2 cells, HEK293T cells, MDCK cells, A549 cells, BHK cells, BHK-21 / BRS cells, Sp2 / 0 cells, HEK293 cells, 293F cells, HeLa cells, TZM-bl cells, Sup-T1 cells, MRC-5 cells, VMK cells, LLC-MK2 cells, HCT-8 cells, Huh-7 cells, and Caco2 cells;

[0066] More preferably, the cell line is selected from the HEK293T cell line or the MDCK cell line;

[0067] Preferably, the cell line is an optional ubiquitin-proteasome system defective cell line; more preferably, the cell line is an E3 ligase knockout or knockdown cell line; 2) Site selection: by statistical analysis of the expression distribution of the ubiquitin-proteasome system in the host, and by bioinformatics and protein structure prediction of the virus, the types of proteolytic targeting molecules to be introduced, the viral proteins and sites of the proteolytic targeting molecules and linker strands to be introduced are determined.

[0068] 3) Gene mutation: Using genetic engineering methods, nucleotide sequences encoding protein hydrolysis target molecules and linker strands are introduced into the coding genes of the identified viral proteins and selected sites.

[0069] 4) Construct an expression vector by operatively linking the coding nucleotide sequence of the viral protein after gene mutation obtained in step 3) to the vector to obtain the expression vector;

[0070] Preferably, the expression vector is a plasmid;

[0071] 5) Using reverse genetics, the expression vector from step 4) and other expression vectors used for influenza virus rescue were co-transfected into a cell line constructed in step 1) that selectively cleaves the linker strand of the proteolytic target virus to obtain the proteolytic target virus.

[0072] Optionally, 6) the protein hydrolysis-targeting virus is replicated in the cell line obtained in step 1) to produce the protein hydrolysis-targeting virus on a large scale;

[0073] Preferably, a proteasome inhibitor is added during the virus preparation; more preferably, the proteasome inhibitor is MG132, MG-341, or lactosin.

[0074] Or the method may include the following steps: ① Site selection: by statistical analysis of the expression distribution of ubiquitin-proteasome system in the host, and by bioinformatics and protein structure prediction of the virus, the types of proteolytic target molecules to be introduced, the viral proteins and sites of the proteolytic target molecules and linker strands to be introduced are determined.

[0075] ② Gene mutation: Using genetic engineering methods, nucleotide sequences encoding protein hydrolysis target molecules and linker strands are introduced into the coding genes of the identified viral proteins and selected sites;

[0076] ③ Construct an expression vector for the mutant sequence, and operatively link the encoding nucleotide sequence of the viral protein after gene mutation obtained in step 3) to the vector to obtain the expression vector;

[0077] Preferably, the expression vector is a plasmid;

[0078] ④ Construct an overexpression vector for a protease that selectively cleaves the linker strand of a virus that targets protein hydrolysis;

[0079] Construct a cell line that can stably express a protease that selectively cleaves the linker strand of a virus that targets proteolytic proteins;

[0080] ⑤ Using reverse genetics technology, the expression vector obtained in step ③, other expression vectors required for virus rescue, and the expression vector obtained in step ④ are co-transfected into host cells. The successfully transfected host cells are cultured in a culture medium to obtain the proteolytic targeted virus.

[0081] According to the method of the present invention, the method further includes step 7):

[0082] Detection: The replication ability of the protein hydrolysis-targeted virus obtained in step 5) in the cell line obtained in step 1) and the unmodified normal host cells is measured to determine whether the protein hydrolysis-targeted virus has been successfully modified. The protein hydrolysis-targeted virus that replicates in the cell line obtained in step 1) and whose replication ability is reduced or cannot replicate in the unmodified normal host cells is a successfully modified protein hydrolysis-targeted virus.

[0083] Optionally, the method further includes step 8):

[0084] Using the successfully modified protein hydrolysis-targeting viral vector, repeat steps 2)-5) to introduce protein hydrolysis-targeting molecules and linker strands onto multiple viral proteins of the protein hydrolysis-targeting virus; or introduce multiple protein hydrolysis-targeting molecules and linker strands onto any viral protein of the protein hydrolysis-targeting virus.

[0085] Optionally, the replication ability of the obtained protein hydrolysis-targeting virus in the cell line obtained in step 1) and in unmodified normal host cells is measured to determine whether the protein hydrolysis-targeting virus has been successfully modified; wherein, the protein hydrolysis-targeting virus that replicates in the cell line obtained in step 1) and whose replication ability is reduced or cannot replicate in unmodified normal host cells is a successfully modified protein hydrolysis-targeting virus.

[0086] According to a specific embodiment of the present invention, a method for the preparation and large-scale production of protein hydrolysis-targeted influenza virus is provided, comprising the following steps:

[0087] 1) Cell line construction: The tobacco plaque virus protease TEVp was stably transduced into mammalian cell lines to construct cell lines that can stably express tobacco plaque virus protease TEVp;

[0088] Preferably, the mammalian cell lines are HEK293T cell lines and MDCK cell lines;

[0089] The stable cell lines constructed were HEK293T-TEVp and MDCK-TEVp. It should be noted that although in this embodiment, Tobacco etch virus protease (TEVp) and its corresponding cleavable sequence are preferred as the research object, those skilled in the art should understand that the principle of this invention can be extended to any other molecule with cleavage function (including proteins, peptides, nucleic acids, and chemical molecules).

[0090] 2) Site selection: By statistically analyzing the expression distribution of the ubiquitin-proteasome system in the host, and by performing bioinformatics and protein structure prediction on influenza viruses, the protein structure of influenza viruses after introducing proteolytic target molecules and linker chains into various proteins of influenza viruses was predicted and analyzed, so as to determine the gene fragments and sites for introducing proteolytic target molecules and linker chains.

[0091] Preferably, one or more insertion sites are selected from gene fragments encoding different proteins of the influenza virus;

[0092] 3) Gene mutation: Using genetic engineering methods, nucleotide sequences encoding protein hydrolysis target molecules and linker strands are introduced into the coding genes of the identified influenza virus proteins and selected sites.

[0093] 4) Constructing plasmids:

[0094] The coding nucleotide sequence of the viral protein obtained in step 3) is operatively ligated to the plasmid to obtain the coding plasmid.

[0095] 5) Using reverse genetics, the plasmid from step 4) was co-transfected with other plasmids used for influenza virus rescue in stable cells that stably expressed TEVp in step 1) to obtain proteolytic targeted influenza virus.

[0096] In this study, the coding nucleotide sequences of the proteolytic target molecule and the tobacco plaque virus protease cleavage sequence were introduced into the genome of the proteolytic target influenza virus, thereby introducing the proteolytic target molecule and the tobacco plaque virus protease cleavage sequence into the protein of the corresponding influenza virus to obtain the proteolytic target molecule modified influenza virus (PROTAC influenza virus).

[0097] Preferably, the method further includes culturing the successfully transfected host cells in DMEM medium containing 0.5% FBS and 2 μg / mL TPCK-trypsin;

[0098] In short, the obtained mutant sequence expression vector was co-transfected into host cells with other plasmids required for virus rescue and plasmids overexpressing TEVp. The successfully transfected host cells were cultured in DMEM medium containing 0.5% FBS and 2 μg / mL TPCK-trypsin.

[0099] Optionally, 6) the protein is hydrolyzed to target influenza virus and produced on a large scale in a stable cell line that stably expresses TEVp;

[0100] Preferably, about 4 days after transfection, or when the packaged virus causes complete or more than 90% of the host cells in 1) to become diseased, the supernatant is collected and used to infect new MDCK-TEVp cells. The culture medium is DMEM medium containing 0.5% FBS and 2 μg / mL TPCK-trypsin. After 4 days of infection, or when the infected virus causes complete disease in the host cells in 1), the supernatant is collected.

[0101] Preferably, the method further includes step 7).

[0102] Detection: The success of the modification of the protein hydrolysis-targeted influenza virus is determined by measuring the dependence of the protein hydrolysis-targeted influenza virus obtained in step 5) on TEVp and the dependence of the inactivation of its packaging products on the proteasome pathway.

[0103] Specifically, the supernatant was centrifuged and filtered through a 0.45 μm filter to remove cell debris. The TEVp-dependent properties of the packaged product were then tested, as well as the dependence of its inactivation on the proteasome pathway. Mutants maintaining TEVp dependence were designated as successful candidates for modification. TEVp dependence of the packaged product refers to the ability of the virus packaged using this method to replicate and proliferate in cell lines with high TEVp expression, while its replication ability is reduced or defective in normal cells that do not express TEVp.

[0104] Optionally, the method further includes step 8):

[0105] Repeat steps 2)-5) using the successfully modified protein hydrolysis-targeted influenza virus vector to introduce protein hydrolysis-targeting molecules and linker chains onto multiple viral proteins of the protein hydrolysis-targeted influenza virus; or introduce multiple protein hydrolysis-targeting molecules and linker chains onto any viral protein of the protein hydrolysis-targeted influenza virus.

[0106] Preferably, the successful modification of the protein hydrolysis-targeted influenza virus is determined by measuring the dependence of the obtained protein hydrolysis-targeted influenza virus on TEVp and the dependence of the inactivation of its packaging products on the proteasome pathway; the protein hydrolysis-targeted virus that retains its dependence on TEVp after long-term passage is considered a candidate for successful modification.

[0107] Optionally, the method further includes

[0108] 9) Select the successfully modified candidate and purify the product;

[0109] 10) Safety or immunogenicity tests were performed on the protein hydrolysis-targeted influenza virus in 9). The safe influenza virus was the successfully modified influenza virus compared to the wild-type virus.

[0110] In one specific embodiment of the invention, PROTAC influenza virus is obtained by inserting the proteolytic-targeting influenza virus gene into a vector (e.g., pHH21 plasmid), and then transfecting the vector, along with other vectors required for rescuing the influenza virus, into a stable cell line that can selectively cleave the proteolytic-targeting molecule, preferably HEK293T-TEVp and MDCK-TEVp. This virus is then amplified in large quantities in a stable cell line that can selectively cleave the proteolytic-targeting molecule, preferably HEK293T-TEVp and / or MDCK-TEVp.

[0111] In one embodiment of the present invention, in order to improve the production efficiency of influenza virus and for future industrial production, the inventors have established a stable cell line (preferably HEK293T-TEVp and MDCK-TEVp) capable of stably expressing the tobacco plaque virus protease TEVp. This stable mammalian cell line also overcomes the drawback of traditional methods of propagating viruses using chicken embryos, which easily cause adverse reactions such as allergies in humans. To further improve production efficiency, an appropriate amount of proteasome inhibitor can be added to the virus culture medium to inhibit the degradation of viral proteins by the ubiquitin-proteasome system; alternatively, cell lines deficient in the ubiquitin-proteasome system, such as E3 ubiquitin ligase knockout or knockdown cell lines, can be used.

[0112] This invention provides a mutant influenza virus, namely PROTAC virus, which can be prepared from mammalian cells and has proteolytically targeted molecules that can be conditionally cleaved introduced into its genome and corresponding proteins. Preferably, the virus is an H1N1, H5N1, H7N9, H3N2, or influenza B virus.

[0113] The aforementioned viruses can also be prepared from stable mammalian cell lines that stably express TEVp (such as 293T cells, MDCK cells, CHO cells, Vero cells, etc.). To further improve yield efficiency, an appropriate amount of proteasome inhibitor can be added to the virus culture medium to inhibit the degradation of viral proteins by the ubiquitin-proteasome system; alternatively, cell lines deficient in the ubiquitin-proteasome system, such as E3 ubiquitin ligase knockout or knockdown cell lines, can be used. The prepared mutant influenza virus exhibits excellent safety and immunomodulatory activity.

[0114] To establish stable mammalian cell lines expressing TEVp, the inventors constructed a lentiviral overexpression vector with puromycin resistance, carrying the TEVp expression gene. This vector was transduced into HEK293T and MDCK cells, respectively, and selected using puromycin to obtain stable cell lines expressing TEVp. These stable cell lines were then cloned and cultured individually. Western blotting and RT-qPCR were used to select the stable cell lines with the highest TEVp expression levels, which became the final stable cell lines, HEK293T and MDCK cells.

[0115] The purified mutant PROTAC influenza virus can be obtained by hollow fiber column chromatography and gel chromatography or by sucrose gradient density centrifugation. Preliminary in vitro and in vivo experiments have demonstrated that the PROTAC influenza virus has excellent safety and genetic stability, and exhibits better immunogenicity compared to inactivated viruses.

[0116] The present invention also provides a method for preparing attenuated live virus, replication-incapable live virus, replication-controllable live virus, and a method for preparing vaccines and drugs for the prevention and treatment of viral infections, the method comprising the step of using the aforementioned protein hydrolysis targeting virus, or the step of preparing the protein hydrolysis targeting virus using the method described above.

[0117] The present invention also provides a vaccine or pharmaceutical composition comprising the aforementioned protein hydrolysate targeting virus;

[0118] Preferably, the vaccine is a live attenuated vaccine, a live attenuated vaccine, or a live attenuated vaccine with controllable replication.

[0119] The present invention also provides a system for preparing the aforementioned proteolytic targeted virus, the system comprising: a cell line stably expressing a protease that selectively cleaves the linker strand of the proteolytic targeted virus; preferably, the cell line is a cell line stably expressing tobacco plaque virus protease TEVp; more preferably, the cell line is a HEK293T cell line or MDCK cell line stably expressing tobacco plaque virus protease TEVp; to further improve the yield efficiency, an appropriate amount of proteasome inhibitor can be added to the virus culture medium to inhibit the degradation of viral proteins by the ubiquitin-proteasome system; or a ubiquitin-proteasome system-deficient cell line, such as an E3 ubiquitin ligase knockout or knockdown cell line, can be used.

[0120] More preferably, the system further includes a nucleic acid vector expressing the proteolytic targeting virus.

[0121] On the other hand, the present invention provides the use of the protein hydrolysis targeting virus of the present invention in the preparation of attenuated live vaccines, replication-incapacitated live vaccines, replication-controllable live vaccines, and the preparation of drugs related to the prevention and treatment of viral infections.

[0122] The present invention also provides a vaccine, wherein the composition contains the PROTAC influenza virus, PROTAC SARS-CoV-2 virus, or PROTAC HIV virus.

[0123] Preferably, the vaccine contains adjuvants and other excipients.

[0124] The present invention also provides a pharmaceutical composition comprising the PROTAC influenza virus, PROTAC SARS-CoV-2 or PROTAC HIV virus, and a pharmaceutically acceptable carrier, diluent or excipient.

[0125] The present invention also provides the use of the aforementioned PROTAC influenza virus, PROTAC SARS-CoV-2 virus, or PROTAC HIV virus in the preparation of attenuated live vaccines, replication-incapacitated live vaccines, replication-controllable live vaccines, and related drugs for the prevention and treatment of viral infections.

[0126] This invention further provides a lentiviral vector carrying the Tobacco etch virus protease (TEVp) gene, the sequence of which is shown below. After packaging the virus into this vector and transducing cells, the Tobacco etch virus protease (TEVp) can be integrated into host cells using puromycin selection. The amino acid sequence of the TEVp is as described in SEQ ID NO:150:

[0127] SEQ ID NO:150:

[0128] MGESLFKGPRDYNPISSTICHLTNESDGHTTSLYGIGFGPFIITNKHLFRRNNGTLLVQSLHGVFKVKNTTTLQQHLIDGRDMIIIRMPKDFPPFPQKLKFREPQREERICLVTTNFQ TKSMSSMVSDTSCTFPSSDGIFWKHWIQTKDGQCGSPLVSTRDGFIVGIHSASNFTNTNNYFTSVPKNFMELLTNQEAQQWVSGWRLNADSVLWGGHKVFMVKPEEPFQPVKEATQLMN

[0129] The present invention also provides stable mammalian cell lines HEK293T-TEVp and MDCK-TEVp that stably express TEVp.

[0130] Among them, the stable cell lines MDCK-TEVp and HEK293T-TEVp are obtained by lentivirus transduction and carry the Tobacco etch virus protease (TEVp) gene. Using this stable cell line, proteolytic targeting molecules with TEVp cleavage sequences as linkers can be introduced into specific sites of any target protein of the virus, so as to realize the large-scale preparation of PROTAC virus.

[0131] The above-mentioned compositions, pharmaceutical compositions, and vaccines can be prepared using conventional techniques in the art based on the site-directed mutation modified PROTAC influenza virus prepared in this invention; they can be used to prevent or treat influenza virus infection, including influenza virus infection in humans and animals.

[0132] Furthermore, this invention provides a live influenza virus vaccine with site-directed mutagenesis, site-directed modification, and controllable replication. The site-directed mutagenesis and modification involve introducing peptides, amino acid sequences, or other molecules that can cause protein degradation (hydrolysis) into any protein of the influenza virus. These introduced peptides, amino acid sequences, or other molecules can be selectively cleaved, inhibited, or inactivated during virus preparation. This invention also relates to the preparation of influenza viruses by combining site-directed mutagenesis-modified sites, introducing peptides, amino acid sequences, or other molecules that can cause protein degradation (hydrolysis) into multiple gene fragments.

[0133] The present invention also provides a method for site-directed mutagenesis and modification of influenza virus, the method comprising introducing any molecule (including polypeptides, amino acid sequences, proteins, or other molecules) capable of causing protein degradation (hydrolysis) into any gene (protein) of influenza virus through zero, one, or more selectively cleavable linkers (including polypeptides, amino acid sequences, proteins, or other molecules). The mutated and modified influenza virus protein can be degraded (hydrolyzed) in a normal host (cell), resulting in a reduction in viral replication capacity (activity) or even complete loss of replication capacity.

[0134] This invention also provides a method for selectively inhibiting viral protein degradation (hydrolysis). The method includes selectively inhibiting or inactivating molecules that can cause protein degradation (hydrolysis) and selectively cleaving the linker chain between the protein degradation molecules and the viral protein to ensure high production efficiency of the virus during preparation. To further improve the production efficiency of PROTAC virus, appropriate amounts of proteasome inhibitors (such as MG132, MG-341, lactacystin, etc.) can be added during PROTAC virus preparation to inhibit proteasome-mediated protein degradation. Alternatively, cells deficient in the ubiquitin-proteasome system can be used for PROTAC virus preparation, such as cell lines with corresponding E3 ligase knockout or knockdown.

[0135] This invention further provides applications for the aforementioned site-directed mutation modified or multi-site combination influenza viruses, such as their use as live influenza vaccines, attenuated vaccines, replication-incompetent vaccines, and safety models of virulent influenza viruses. The technology in this invention can be widely used for the modification and preparation of any virus, and its application in live vaccines, attenuated vaccines, inactivated vaccines, and safety models of virulent viruses.

[0136] Compared with the prior art, the present invention has the following advantages:

[0137] 1) Versatility: All viruses have proteins. By introducing "cleavable proteolytic targeting molecules" into the viral proteins that need to be degraded, viral replication can be controlled. Therefore, this technology can be used to prepare vaccines for all viruses.

[0138] 2) There are thousands of protein hydrolysis targeting molecules available, all of which can be developed and utilized to prepare this viral vaccine. Therefore, there is a wealth of resources to choose from.

[0139] 3) Simple operation: Only simple viral vector construction and virus preparation technology are required. Producers do not even need much knowledge of viral biology to prepare this type of vaccine.

[0140] 4) Experiments have shown that this technology can be used to design vaccines with different degrees of inactivation, and it is safe and controllable.

[0141] 5) Experiments have shown that this type of vaccine has good immunogenicity. Attached Figure Description

[0142] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings, wherein:

[0143] Figure 1 A map of TEVp-overexpressing lentiviral vectors;

[0144] Figure 2A Electrophoresis image for RT-PCR identification of potential HEK293T-TEVp cells (the cells indicated by the arrows are cells with relatively high mRNA expression levels of the target gene TEVp). Figure 2B Electrophoresis image for RT-PCR identification of potential MDCK-TEVp cells (O (old) represents the first batch of MDCK cells; N (new) represents the second batch of MDCK cells; cells indicated by arrows are those with relatively high mRNA expression levels of the target gene TEVp).

[0145] Figure 3 The graph shows the expression of the target protein TEVp in the HEK293T-TEVp and MDCK-TEVp cell lines prepared according to the method of the present invention, and the graph shows the viral packaging efficiency.

[0146] Figure 4 The bar graph shows the replication titer of the protein hydrolysis-targeted influenza virus (PROTAC influenza virus) prepared according to the method of the present invention after 2 days of infection in MDCK-TEVp cell line and normal cell line.

[0147] Figure 5A bar graph showing the infection and replication titers of the proteolytic targeted influenza virus (PROTAC influenza virus) containing multiple proteolytic molecules prepared according to the method of the present invention in the MDCK-TEVp cell line and normal cell line.

[0148] Figure 6 A bar graph comparing the replication capacity of the proteolytic targeted influenza virus (PROTAC influenza virus) prepared according to the method of the present invention in MDCK-TEVp cells and normal cell lines.

[0149] Figure 7 The genetic stability of the protein hydrolysis-targeted influenza virus (PROTAC influenza virus) prepared according to the method of the present invention was investigated to demonstrate that the prepared PROTAC influenza virus remains stable after multiple passages.

[0150] Figure 8 A graph showing the proteasome degradation of the PROTAC influenza virus according to the present invention in normal cells using a western blot experiment.

[0151] Figure 9 Immunofluorescence assays were performed to evaluate the replication of the PROTAC influenza virus according to the present invention in the MDCK-TEVp cell line and normal cells.

[0152] Figure 10 Animal-level immunogenicity and protective effects of the PROTAC virus according to the present invention;

[0153] Figure 11 A flowchart of a method for preparing a protein hydrolysis-targeted virus according to the present invention is provided. Detailed Implementation

[0154] To better understand this invention, the inventors have illustrated and explained specific experiments using examples. These examples are for illustrative purposes only and do not limit the scope of protection of this invention. Any variations or embodiments equivalent to this invention are included in this invention.

[0155] Example 1: Establishment of stable mammalian cell lines HEK293-TEVp and MDCK-TEVp that can stably express TEVp

[0156] The development of this stable TEVp-expressing mammalian cell line was commissioned and assisted by Beijing CorreGene Biotechnology Co., Ltd.

[0157] (1) Construction of TEVp overexpression lentiviral vector:

[0158] TEVp overexpression lentiviral vector map as follows: Figure 1 As shown. The lentiviral vector is resistant to puromycin.

[0159] (2) Lentiviral packaging, purification and quantification

[0160] ① Day 0 cell seeding: 293T cells were seeded in 10cm / 15cm culture dishes (the seeding number was determined by the expected viral load, 1×10^8 / 15cm culture dish), and the seeding density was controlled. The cells were allowed to grow to 80% confluence on the second day.

[0161] ② Day 1 plasmid transfection: 293T cells were co-transfected using the TEVp overexpression lentiviral vector, psPAX2 plasmid (which can be obtained from addgene) and pVSVG plasmid (which can be obtained from addgene) described in (1);

[0162] ③ Change the medium on the second day: Change the medium 18 hours after transfection (the transfection system is toxic), completely aspirate the culture medium, and carefully add 20 mL of fresh complete culture medium (15 cm petri dish);

[0163] ④ Virus supernatant pretreatment: After collecting the virus supernatant on days 3, 4 and 5, the culture supernatant was transferred to a 50 mL centrifuge tube and centrifuged at the highest speed for 10 min; the virus supernatant was filtered using a 0.45 μm filter and collected directly using a sterilized 250 mL centrifuge bottle;

[0164] ⑤ High-speed centrifugation to purify the virus: Use a 20mL syringe to slowly inject 10% sucrose solution into the bottom of the centrifuge bottle, maintaining a volume ratio of 4:1 (4 parts virus supernatant, 1 part sucrose solution), centrifuge at 4℃ and 14000rpm for 2 hours.

[0165] ⑥ Virus resuspension: Discard the supernatant, aspirate thoroughly, add 100ul-1000ul PBS, and mix well by pipetting and aspiration;

[0166] ⑦ Aliquot the virus supernatant and freeze at -80 degrees Celsius; freeze the remaining approximately 30 μL separately for titer determination.

[0167] ⑧ The lentivirus titer was determined using chemiluminescence immunoassay (CMIA). The titer of pLenti-CMV-puro-2A-TEVp-8534bp was confirmed to be 5.12E+7TU / mL. The volume was 1000ul, and the total amount was 5.12E+7TU, which met the transduction requirements.

[0168] (3) Construction of stable monoclonal cell lines

[0169] ① Day 0 cell seeding: HEK293T or MDCK cells were seeded in 12 / 6-well plates (the seeding number was determined by the expected viral load, 1×10^6 / 6-well plate), and the seeding density was controlled. The cells were allowed to grow to 20-30% confluence on the second day.

[0170] ② Thawing the virus on day 1: Remove the virus from the -80℃ freezer and thaw it on ice. Infect cells with a suitable MOI (MOI = 10).

[0171] ③ Day 2 Virus transduction: Infect cells with appropriate moi for 24 hours, then switch to 2 μg / mL puro resistance medium for resistance screening.

[0172] ④ Continuous resistance screening for about 7 days (all blank control cells were killed).

[0173] ⑤ Digest and count the surviving cells, and distribute them evenly into 96-well plates at a ratio of 100 / 200 cells. (On average, there should be 1-2 cells per well)

[0174] ⑥ Clonal proliferation can be observed in 3-5 days. Select single-clone cells from the wells and proliferate them, gradually expanding to 24-well plates and then 12-well plates.

[0175] ⑦ Monoclonal identification:

[0176] Identification primers

[0177] TEVp-F:

[0178] SEQ ID NO:151TCATTACAAACAAGCACTTG

[0179] TEVp-R:

[0180] SEQ ID NO:152TAGGCATGCGAATAATTATC

[0181] Fragment size: 144bp

[0182] 293t-GAPDH-eF:

[0183] SEQ ID NO:153CCACATCGCTCAGACACCAT

[0184] 293t-GAPDH-eR:

[0185] SEQ ID NO:154GGCAACAATATCCACTTTACCAGAGT

[0186] Fragment size: 114bp

[0187] Selected cell clones were digested, RNA was extracted, and RT-PCR was performed to identify and verify whether TEVp was integrated and expressed in the cells. Amplification conditions are shown in Table 1 below:

[0188] Table 1 Amplification conditions

[0189]

[0190]

[0191] The results are shown in Figure 2. Figure 2A Electrophoresis image for RT-PCR identification of potential HEK293T-TEVp cells (cells indicated by arrows are those with relatively high mRNA expression levels of the target gene TEVp). This validation work was commissioned to CorreGene (Beijing) Co., Ltd. Figure 2B Electrophoresis image for RT-PCR identification of potential MDCK-TEVp cells (O (old) represents the first batch of MDCK cells; N (new) represents the second batch of MDCK cells; cells indicated by arrows are those with relatively high mRNA expression levels of the target gene TEVp). This validation work was commissioned to CorreGene (Beijing) Co., Ltd.

[0192] ⑧Optimal expansion culture of monoclonal cell lines

[0193] Cell lines with high TEVp expression efficiency were selected for expansion and cryopreservation for later use, and were named HEK293T-TEVp and MDCK-TEVp, respectively.

[0194] The results are as follows Figure 3 As shown, Western blot analysis of HEK293T-TEVp and MDCK-TEVp cell lines using anti-TEVp antibody revealed that the tobacco plaque virus protease TEVp could be efficiently and stably expressed in stable HEK293T-TEVp and MDCK-TEVp cell lines. Furthermore, cell modification did not alter viral production efficiency, demonstrating TEVp's compatibility within the cells.

[0195] Example 2: Construction of a gene vector for influenza virus (WSN) containing cleavable proteolytic targeting molecules

[0196] (1) Obtaining plasmids for rescuing wild-type influenza virus (WSN):

[0197] According to the gene sequence of influenza virus A / WSN / 1933 published by PubMed

[0198] https: / / www.ncbi.nlm.nih.gov / nuccore / ?term=WSN+PB2 ;

[0199] https: / / www.ncbi.nlm.nih.gov / nuccore / ?term=WSN+PB1 ;

[0200] https: / / www.ncbi.nlm.nih.gov / nuccore / ?term=WSN+PA ;

[0201] https: / / www.ncbi.nlm.nih.gov / nuccore / ?term=WSN+HA ;

[0202] https: / / www.ncbi.nlm.nih.gov / nuccore / ?term=WSN+NA ;

[0203] https: / / www.ncbi.nlm.nih.gov / nuccore / ?term=WSN+NP;

[0204] https: / / www.ncbi.nlm.nih.gov / nuccore / ?term=WSN+M ;

[0205] The genome of the influenza virus was obtained by synthesizing the complete genome of WSN from https: / / www.ncbi.nlm.nih.gov / nuccore / ?term=WSN+NS. These genomes were then ligated into pHH21, pCDNA3(neo), and pcAAGGS / MCS vectors (obtained from Beijing Zhongke Yubo Biotechnology Co., Ltd.) to obtain plasmids for rescuing the wild-type influenza virus WSN. The naming and composition of the obtained plasmids are shown in Table 2 below.

[0206] Table 2

[0207] Abbreviation plasmid name Key genes Enzyme cleavage sites well constructed plasmid structure Ben1 PHH21 PB2 BsmBI pPolI-WSN-PB2 Ben2 PHH21 PB1 BsmBI pPolI-WSN-PB1 Ben3 PHH21 PA BsmBI pPolI-WSN-PA Ben4 PHH21 HA BsmBI pPolI-WSN-HA Ben5 PHH21 NP BsmBI pPolI-WSN-NP Ben6 PHH21 NA BsmBI pPolI-WSN-NA Ben7 PHH21 M BsmBI pPolI-WSN-M Ben8 PHH21 NS BsmBI pPolI-WSN-NS Ben9 pcDNA3(neo) PB2 EcoRI pcDNA3(neo)-PB2 Ben10 pcDNA3(neo) PB1 EcoRI pcDNA3(neo)-PB1 Ben11 pcDNA3(neo) PA EcoRI pcDNA3(neo)-PA Ben13 pcAGGS / MCS NP EcoRI pcAGGS / MCS-NP

[0208] (2) Construction of viral vectors that introduce cleavable proteolytic targeting molecules

[0209] The inventors introduced gene sequences of proteolytic target molecules that can be cleaved by TEVp into the C-terminus and before the stop codon of the gene coding regions corresponding to various viral proteins (PA, PB2, PB1, NP, HA, NA, M1, M2, NS1, NEP) of influenza virus WSN, and constructed the following viral vectors.

[0210] Specifically, the gene sequence of the proteolytic targeting molecule that can be cleaved by TEVp and its expressed amino acid sequence were introduced onto any protein of the virus, as shown below, but not limited to, the following sequences. The gene sequence corresponding to the used amino acid sequence was humanized and optimized, and then inserted into the C-terminus of the coding region of the target protein gene before the stop codon. This work was completed with the assistance of Beijing Qingke Biotechnology Co., Ltd., and the successful mutation construction was verified by sequencing. Among them:

[0211] 1) Introduce the sequence shown in SEQ ID NO:138 at the C-terminus of the PA protein of influenza virus, that is, introduce the nucleotide sequence shown in SEQ ID NO:155 at the C-terminus of the coding region of its PA protein gene before the stop codon, and name it PA-TEVcs+PROTAC-1 (or PA-PTD1).

[0212] SEQ ID NO:138

[0213] GSGGENLYFQGGSGALAPYIP;

[0214] SEQ ID NO:155

[0215] GGTTCTGGTGGTGAGAAT CTGTAC TTC CAAGGTGGATCTGGAGCA TTG GCC CCC TACATTCCA;

[0216] 2) Similarly, the sequence shown in SEQ ID NO:138 is introduced at the C-terminus of the M1 protein of influenza virus, that is, the nucleotide sequence shown in SEQ ID NO:155 is introduced at the C-terminus of its PA protein gene coding region before the stop codon, and it is named M1-TEVcs+PROTAC-1 (or M1-PTD1).

[0217] 3) Introduce the sequence shown in SEQ ID NO:139 at the C-terminus of the PB1 protein of the influenza virus, that is, introduce the nucleotide sequence shown in SEQ ID NO:156 at the C-terminus of the coding region of the PB1 protein gene, before the stop codon, and label it as PB1-TEVcs+PROTAC-2 (or named PB1-PTD2):

[0218] SEQ ID NO:139

[0219] GSGGENLYFQGGSGDRHDSGLDSM

[0220] SEQ ID NO:156GGTTCTGGTGGTGAG AAT CTGTAC TTC CAA GGTGGATCTGGAGAT CGCCAC GAT TCA GGG CTC GAT TCC ATG

[0221] 4) Introduce the sequence shown in SEQ ID NO:139 at the C-terminus of the PB2 protein of the influenza virus, that is, introduce the nucleotide sequence shown in SEQ ID NO:156 at the C-terminus of the coding region of the PB2 protein gene, before the stop codon, and label it as PB2-TEVcs+PROTAC-2 (or named PB2-PTD2):

[0222] 5) Introduce the sequence shown in SEQ ID NO:139 at the C-terminus of the M1 protein of the influenza virus, that is, introduce the nucleotide sequence shown in SEQ ID NO:156 at the C-terminus of the coding region of the M1 protein gene before the stop codon, and label it as M1-TEVcs+PROTAC-2 (or named M1-PTD2).

[0223] 6) Introduce the sequence shown in SEQ ID NO:140 at the C-terminus of the PA protein of influenza virus, that is, introduce the nucleotide sequence shown in SEQ ID NO:157 at the C-terminus of its PA protein gene coding region before the stop codon, and name it PA-TEVcs+PROTAC-3 (or PA-PTD3).

[0224] SEQ ID NO:140:

[0225] GSGGENLYFQGGGGSSHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV;

[0226] SEQ ID NO:157

[0227] GGTTCTGGTGGTGAGAATCTGTACTTCCAAGGTGGAGGAGGATCCAGCCATGGCTTCCCGCCGGAGGTGGAGGAGCAGGATGATGGCACGCTGCCCATGTCTTGTGCCCAGGAGAGCGGGATGGACCGTCACCCTGCAGCCTGTGCTTCTGCTAGGATCAATGTG

[0228] 7) Combine PA-TEVcs+PROTAC-1 (PA-PTD1) and PB1-TEVcs+PROTAC-2 (PB1-PTD2) to construct viruses in which PA and PB1 each carry a protein hydrolysate molecule that can be cleaved.

[0229] Furthermore, the inventors constructed the following viral vector:

[0230] Table 3 Viral vectors

[0231]

[0232]

[0233]

[0234] Table 3 (continued) Viral vectors

[0235]

[0236]

[0237] Example 3: Rescue of PROTAC influenza virus modified by site-directed mutagenesis

[0238] Following standard influenza virus rescue methods, 12 plasmids used for influenza virus rescue were co-transfected into stable cell lines, and the corresponding plasmids in these 12 plasmids were replaced with the site-directed mutagenesis-modified plasmids described in Example 2. 0.2 μg of each plasmid was added to each well of a six-well plate. After transfection, cytopathic effects on the cells were observed, and insertion sites, proteolytic targeting molecules, linkers cleavable by TEVp, and combinations thereof that could rescue the virus were screened. The selected strains were named based on the proteins and the introduced cleavable proteolytic targeting molecules.

[0239] For example, after introducing the cleavable proteolytic targeting molecule TEVcs+PROTAC-1 onto the Ben3 pPolI-WSN-PA plasmid, this plasmid was combined with other plasmids for rescuing influenza viruses: Ben1 pPolI-WSN-PB2; Ben2 pPolI-WSN-PB1; Ben4 pPolI-WSN-HA; Ben5 pPolI-WSN-NP; Ben6 pPolI-WSN-NA; Ben7 pPolI-WSN-M; Ben8 pPolI-WSN-NS; Ben9 pcDNA 3(neo)-PB2; Ben10 pcDNA 3(neo)-PB1; Ben11 pcDNA3(neo)-PA; Ben13 The stable cell line established in Case 1 was co-transfected with pcAGGS / MCS-NP, thereby rescuing the mutant influenza virus with TEVCs+PROTAC-1 introduced into the PA gene fragment of the influenza virus, named PA-TEVcs+PROTAC-1 (or PA-PTD1). After introducing the cleavable proteolytic targeting molecule TEVcs+PROTAC-1 into the C-terminus of the coding region of the M1 protein on the Ben7 pPolI-WSN-M plasmid, this plasmid was combined with other plasmids for rescuing influenza viruses: Ben1 pPolI-WSN-PB2; Ben2 pPolI-WSN-PB1; Ben3 pPolI-WSN-PA; Ben4 pPolI-WSN-HA; Ben5 pPolI-WSN-NP; Ben6 pPolI-WSN-NA; Ben8 pPolI-WSN-NS; Ben9 pcDNA 3(neo)-PB2; Ben10 pcDNA3(neo)-PB1; Ben11 pcDNA The stable cell line established in Case 1 was co-transfected with 3(neo)-PA; Ben13pcAGGS / MCS-NP to rescue the mutant influenza virus with TEVCs+PROTAC-1 introduced into the M1 gene fragment of the influenza virus, named M1-TEVcs+PROTAC-1 (or M1-PTD1).

[0240] Using the same method, mutant influenza viruses with cleavable proteolytic target molecules introduced at other sites can be obtained and named according to the same rules.

[0241] All constructed PROTAC viral vectors were examined according to the criterion of inducing cytopathic effects: if they induced cytopathic effects in HEK293T-TEVp and / or MDCK-TEVp, the PROTAC virus was successfully rescued; if they did not induce cytopathic effects in HEK293T-TEVp and / or MDCK-TEVp, the PROTAC virus was rescued unsuccessfully. The rescue results of some mutant influenza viruses are shown in Table 4 and [other tables not provided in the original text]. Figure 4 Table 4 summarizes some PROTAC influenza virus strains that can cause lesions in MDCK-TEVp cells. Figure 4 The study presented viral titers in cell supernatants detected on the second day after inoculation of some influenza virus strains into MDCK-TEVp cells and normal MDCK cells (MOI = 0.01). These results indicate that selectively cleavable proteolytic targeting molecules can be introduced into eight gene fragments of the influenza virus, among which PA, PB2, PB1, and M1 can rescue PROTAC influenza virus.

[0242] Table 4. Some PROTAC influenza virus strains that cause lesions in MDCK-TEVp cells.

[0243]

[0244] The inventors selected mutation modification methods from the aforementioned mutation sites and cleavable proteolytic targeting molecules that are highly efficient at rescuing influenza viruses, genetically stable, and whose replication ability is significantly reduced or even completely lost in normal host cells. These methods were combined to prepare influenza viruses containing multiple proteolytic targeting molecules. Further preferred strains were selected and named M1-TEVcs+PROTAC-1+PROTAC-2 (or M1-PTD6), M1-TEVcs+PROTAC-2+PROTAC-1 (or M1-PTD5), and PROTAC-V1 (Table 4 and...). Figure 5The M1-TEVcs+PROTAC-1+PROTAC-2 strain is a PROTAC strain containing two proteolytic targeting molecules, prepared by introducing PROTAC-1 and PROTAC-2 in tandem at the C-terminus of the M1 protein of the virus; the M1-TEVcs+PROTAC-2+PROTAC-1 strain is a PROTAC strain containing two proteolytic targeting molecules, prepared by introducing PROTAC-2 and PROTAC-1 in tandem at the C-terminus of the M1 protein of the virus; PROTAC-V1 is a PROTAC strain containing two proteolytic targeting molecules, prepared by introducing TEVcs-PROTAC-1 at the C-terminus of the PA protein of the virus and TEVcs-PROTAC-2 at the C-terminus of the PB1 protein of the virus (Table 4). Further, Figure 11 A flowchart for preparing protein hydrolysis-targeted viruses according to the method of the present invention is provided.

[0245] Example 4: Expression and purification of site-directed mutagenesis-based influenza virus

[0246] 1) Rescue of PROTAC viruses containing cleavable proteolytic targeting molecules

[0247] The mutant influenza virus packaging plasmid obtained from the site-directed mutagenesis-modified influenza virus rescue in Example 3 was co-transfected into the stable cell line in Example 1. After 6 hours, the medium was replaced with fresh medium containing 1% FBS and 2 μg / mL TPCK-trypsin, with normal cells as a control. The positive control used in this rescue experiment was wild-type influenza virus (WSN). Except for the plasmid used to rescue the virus, all other conditions were the same as those for the mutant influenza virus rescue. After transfection, the cell status was observed daily. Mutants that showed pathological changes in TEVp-stabilized cell lines, while normal cells showed no or minimal pathological changes, were considered positive mutants. Wild-type influenza virus showed pathological changes in both TEVp-stabilized and normal cell lines.

[0248] 2) Purification of PROTAC influenza virus

[0249] a. When the stable cell line of the rescued mutant PROTAC influenza virus in step 1) becomes completely cytopathic, or about 4 days after transfection, collect the cell supernatant, centrifuge at 5000g for 10 min, and amplify it in large quantities with a new stable cell line. When the cells become completely cytopathic or about 4 days after amplification, collect the cell supernatant and filter it through a 0.45μm filter membrane.

[0250] b. Purify the influenza virus using a sucrose gradient density centrifugation method. The specific steps are as follows: Transfer the virus solution from step 1) into a 50 mL centrifuge tube (high-speed centrifuge) at 10... 5 Centrifuge for 2 hours, then resuspend the precipitate in 1 mL of PBS.

[0251] c. Dissolve sucrose in NTE buffer (100mM NaCl, 10mM Tris-Cl, pH 7.4, 1mM EDTA) to prepare a 20% sucrose solution, and filter it through a 0.45μm filter membrane.

[0252] d. Add the sucrose from step 3) to a 50 mL or 15 mL centrifuge tube, and drop the PBS resuspended solution from step 2) onto the sucrose solution. 11 × 10 4 g, centrifuged for 2 hours.

[0253] e. Add approximately 15 mL of NTE buffer to the precipitate, then add 11 × 10⁻⁶ ml of solution. 4 g, continue centrifugation for 2 hours.

[0254] f. Resuspend the precipitate from step 5) with PBS.

[0255] Example 5: Safety study of protein hydrolysis targeting influenza virus at the cellular level

[0256] The inventors confirmed the safety of the PROTAC virus by examining the dependence of the prepared mutant PROTAC influenza viruses M1-TEVcs+PROTAC-1, M1-TEVcs+PROTAC-2, M1-TEVcs+PROTAC-1+PROTAC-2, and M1-TEVcs+PROTAC-2+PROTAC-1 on the TEVp protein; and conducted long-term passage culture to examine the stability of the cleavable proteolytic target molecules in the mutant virus.

[0257] Experiment 1: The prepared mutant PROTAC influenza virus was used to infect MDCK-TEVp cells and normal MDCK cells at an MOI ratio of 0.01. After 3-4 days, the supernatant was collected to detect the viral titer. The viral titer of PROTAC virus in MDCK-TEVp cells was set as 100%. By comparing the relative viral titers of PROTAC virus in MDCK-TEVp cells and normal MDCK cells, the difference in viral replication ability between the two cell types can be determined.

[0258] Experiment 2: Newly prepared mutant PROTAC influenza virus was inoculated into fresh culture medium at an MOI of 0.01 and used to infect stable cell lines. The culture medium contained 1% FBS and 2 μg / mL TPCK-trypsin, with a normal cell line as a control. After the TEVp stable cell lines had fully developed cytopathic effects, the supernatant was collected, filtered through a 0.45 μm filter, and then inoculated into fresh culture medium again at an MOI of 0.01 to infect stable cell lines, again using a normal cell line as a control. This process was repeated for long-term viral passage. Gene sequencing was used to detect whether the introduced proteolytic targeting molecules had mutated.

[0259] Depend on Figure 6 It can be seen that the PROTAC virus can replicate and proliferate in MDCK-TEVp cells, while its replication ability is significantly reduced or even impossible in normal MDCK cells, indicating a dependence on TEVp and suggesting that the virus is safe. Figure 7 It can be seen that, after long-term passage, the proteolytic targeting molecule introduced into the mutant PROTAC virus strain has not mutated. This indicates that the cleavable proteolytic targeting molecule introduced into the influenza virus gene is stable, and thus genetically stable.

[0260] Example 6. Investigating whether the reduced ability of proteolytic targeting of influenza virus replication is due to the cellular proteasome. Regulation

[0261] Using M1-TEVcs+PROTAC-1 and M1-TEVcs+PROTAC-2 as representative strains, the inventors investigated whether the reduced replication ability of the designed PROTAC influenza virus in normal cells was mediated by the intracellular ubiquitin-proteasome system.

[0262] Experiment 1: Normal MDCK cells were infected with either the prepared mutant PROTAC influenza virus or wild-type virus (MOI = 0.1). The culture medium was supplemented with 100 nM proteasome inhibitor MG-132 or DMSO at the same dilution as a control. Cell samples were collected at 24 and 48 hours post-infection, and the viral M1 protein level was detected by Western blot.

[0263] Experiment 2: MDCK-TEVp cells and normal MDCK cells (MOI = 0.01) were infected with either the prepared mutant PROTAC influenza virus or wild-type virus. Different concentrations (0, 50, or 100 nM) of the proteasome inhibitor MG-132 or DMSO at the same dilution were added to the culture medium as controls. Forty-eight hours post-infection, the cells were fixed with 4% PFA, and the viral NP protein level was detected using immunofluorescence.

[0264] Depend on Figure 8 It was found that wild-type virus can replicate extensively and produce large amounts of viral proteins after infecting MDCK cells. In contrast, when the viral protein M1 of PROTAC virus is modified with the proteolysis targeting molecules TEVcs+PROTAC-1 or TEVcs+PROTAC-2, the viral M1 protein is degraded 48 hours after infection; and the addition of the proteasome inhibitor MG-132 to the culture medium inhibits the proteasome-mediated degradation of viral protein M1. These experimental results demonstrate that the proteolysis targeting molecules introduced by the inventors can mediate the degradation of viral proteins.

[0265] The reduced replication capacity of PROTAC virus in normal cells is caused by the degradation of viral proteins mediated by the proteasome, which is consistent with the inventor's principle.

[0266] Depend on Figure 9 Immunofluorescence experiments showed that PROTAC virus could replicate extensively and synthesize large amounts of viral proteins after infecting MDCK-TEVp cells. However, PROTAC virus could not replicate extensively in normal MDCK cells, resulting in a lower detection of viral protein NP signals. When the proteasome system was inhibited, the signal of viral protein NP increased, indicating that viral replication was enhanced when the proteasome system was inhibited. These results are consistent with... Figure 8 The results were consistent, further demonstrating that the introduction of proteolytic targeting molecules mediates the degradation of viral proteins by the cell's proteasome, thereby inhibiting viral replication; when the cell's proteasome system is inhibited, viral replication recovers.

[0267] The above results demonstrate that the reduced or defective replication ability of the PROTAC virus is mediated by the cell's ubiquitin-proteasome system, which is consistent with the inventors' design expectations for the PROTAC virus.

[0268] Example 7. Immunogenicity and protective properties of protein-hydrolyzed targeted influenza virus (PROTAC influenza virus) at the animal level Protective assessment

[0269] In this study, ferrets (provided by Cay Ferret Farm in Wuxi, Jiangsu, China) were used to evaluate the immunogenicity and efficacy of PROTAC virus at the animal level. An inactivated influenza vaccine (IIV) was used as a control (the inactivated influenza virus vaccine was prepared by the inventors using homologous influenza virus particles according to the method provided in the Chinese Pharmacopoeia). M1-TEVcs+PROTAC-1 was selected as a representative PROTAC virus for evaluation of its immunogenicity and protective effect.

[0270] Specific experiment:

[0271] 1) Divide nine 4-6 month old female ferrets into three groups of three.

[0272] 2) Viral vaccine administration: Group 1 received PBS via nasal drops; Group 2 received 10g of PBS via nasal drops. 5 PFU M1-TEVcs-PROTAC-1; the third group was inoculated with the same dose of inactivated virus.

[0273] 3) Three weeks after vaccination, serum was collected from each group for hemagglutination inhibition (HI) test and neutralizing (NT) antibody detection.

[0274] 4) Three weeks after vaccination, each group of animals was injected intranasally with 10 7Wild-type virus WSN of PFU.

[0275] 6) Three days after inoculation with wild-type virus, lung tissue was taken and the viral load was measured using a plaque assay.

[0276] The results are as follows Figure 10 As shown, PROTAC virus can induce high levels of hemagglutination inhibition antibody titers (A) and neutralizing antibody titers (B) in animals. The levels of hemagglutination inhibition and neutralizing antibodies induced by PROTAC virus are significantly higher than those induced by inactivated vaccines. PROTAC virus vaccination can significantly reduce wild-type virus titers in animal lung tissue (C); the protection provided by PROTAC virus vaccine is significantly superior to that of inactivated vaccines.

[0277] The above descriptions are merely some embodiments of the present invention. Those skilled in the art can make various modifications and improvements without departing from the inventive concept of the present invention, and these all fall within the scope of protection of the present invention.

[0278] References

[0279] [1]Kathleen M.Sakamoto et al.Protacs:Chimeric molecules that targetproteins to the Skp1–Cullin–F box complex for ubiquitination anddegradation.PNAS(2001).

[0280] [2]Ashley R.Schneekloth et al. Targeted intracellular protein degradation induced by a small molecule:En route to chemicalproteomics.Bioorganic&Medicinal Chemistry Letters(2008).

[0281] [3]Dennis L.Buckley et al.Small-Molecule Inhibitors of theInteraction between the E3 Ligase VHL and HIF1α.Angewandte ChemieInternational Edition(2012).

[0282] [4]Daniel P Bondeson et al.Catalytic in vivo protein knockdown bysmall-molecule PROTACs.Nature Chemical Biology(2015).

[0283] [5]Georg E.Winter et al.Phthalimide conjugation as a strategy for invivo target protein degradation.Science(2015).

[0284] [6]Michael Zengerle et al.Selective Small Molecule InducedDegradation of the BET Bromodomain Protein BRD4.ACS Chemical Biology(2015).

[0285] [7]Dennis L.Buckley et al.HaloPROTACS:Use of Small Molecule PROTACsto Induce Degradation of HaloTag Fusion Proteins.ACS Chemical Biology(2015).

[0286] [8]Jing Lu et al.Hijacking the E3 Ubiquitin Ligase Cereblon toEfficiently Target BRD4.Chemical Biology(2015).

[0287] [9]Yonghui Sun et al.PROTAC-induced BTK degradation as a noveltherapy for mutated BTK C481S induced ibrutinib-resistant B-cellmalignancies.Cell Research(2018).

[0288]

[10] Yonghui Sun et al. Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkinlymphomas. Leukemia (2019).

[0289]

[11] Richard R.Furman et al.Ibrutinib resistance in chroniclymphocytic leukemia.NEJM(2014).

[0290]

[12] Mariell Pettersson et al. PROteolysis TArgeting Chimeras (PROTACs)-Past, present and future. Drug Discovery Today: Technologies (2019)). sequence list <110> Si Longlong Zhen Zhaoyu Niu Siwen <120> Protein hydrolysis targeting viruses, their live vaccines, their preparation methods and uses <130> DIC19110060R <150> 2019106036989 <151> 2019-07-05 <160> 170 <170> SIPOSequenceListing 1.0 <210> 1 <211> 7 <212> PRT <213> Artificial Sequence <400> 1 Ala Leu Ala Pro Tyr Ile Pro 1 5 <210> 2 <211> 10 <212> PRT <213> Artificial Sequence <400> 2 Asp Arg His Asp Ser Gly Leu Asp Ser Met 1 5 10 <210> 3 <211> 40 <212> PRT <213> Artificial Sequence <400> 3 Ser His Gly Phe Pro Pro Glu Val Glu Glu Gln Asp Asp Gly Thr Leu 1 5 10 15 Pro Met Ser Cys Ala Gln Glu Ser Gly Met Asp Arg His Pro Ala Ala 20 25 30 Cys Ala Ser Ala Arg Ile Asn Val 35 40 <210> 4 <211> 30 <212> PRT <213> Artificial Sequence <400> 4 Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr 1 5 10 15 Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala 20 25 30 <210> 5 <211> 6 <212> PRT <213> Artificial Sequence <220> <221> SITE <222> (4)..(4) <223> Xaa indicates that it can be any amino acid. <220> <221> SITE <222> (5)..(5) <223> Xaa indicates that it can be any amino acid. <220> <221> UNSURE <222> (4)..(4) <223> The 'Xaa' at location 4 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (5)..(5) <223> The 'Xaa' at location 5 stands for Gln, Arg, Pro, or Leu. <400> 5 Asp Ser Gly Xaa Xaa Ser 1 5 <210> 6 <211> 10 <212> PRT <213> Artificial Sequence <220> <221> SITE <222> (7)..(7) <223> XAA indicates that it can be any amino acid. <220> <221> SITE <222> (8)..(8) <223> XAA indicates that it can be any amino acid. <220> <221> UNSURE <222> (7)..(7) <223> The 'Xaa' at location 7 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (8)..(8) <223> The 'Xaa' at location 8 stands for Gln, Arg, Pro, or Leu. <400> 6 Asp Arg His Asp Ser Gly Xaa Xaa Ser Met 1 5 10 <210> 7 <211> 12 <212> PRT <213> Artificial Sequence <400> 7 Leu Gly Ser Trp Arg His Trp Arg Gly Gln Glu Gly 1 5 10 <210> 8 <211> 13 <212> PRT <213> Artificial Sequence <400> 8 Ser Leu Tyr Lys Lys Val Val Gly Thr Met Ala Ala Gly 1 5 10 <210> 9 <211> 12 <212> PRT <213> Artificial Sequence <400> 9 Met Leu Ser Glu Ser Arg Asn Phe Pro Ala Gln Ala 1 5 10 <210> 10 <211> 12 <212> PRT <213> Artificial Sequence <400> 10 Glu Arg Ala Pro Thr Gly Arg Trp Gly Arg Arg Gly 1 5 10 <210> 11 <211> 12 <212> PRT <213> Artificial Sequence <400> 11 Lys Lys Val Gly Arg Ala Arg Pro Cys Gln Arg Gly 1 5 10 <210> 12 <211> 12 <212> PRT <213> Artificial Sequence <400> 12 Ala Pro Arg Ala Pro Arg Gln Arg Ser Arg Asp Gly 1 5 10 <210> 13 <211> 11 <212> PRT <213> Artificial Sequence <400> 13 Ser Trp Arg Leu Thr Gly Ser Gly Met Lys Gly 1 5 10 <210> 14 <211> 12 <212> PRT <213> Artificial Sequence <400> 14 Trp Arg Pro Gly Arg Arg Gly Pro Ser Ser Gly Gly 1 5 10 <210> 15 <211> 12 <212> PRT <213> Artificial Sequence <400> 15 Leu Arg Gly Pro Ser Pro Pro Pro Met Ala Gly Gly 1 5 10 <210> 16 <211> 12 <212> PRT <213> Artificial Sequence <400> 16 Trp Arg Pro Gly Arg Arg Gly Pro Ser Ser Gly Gly 1 5 10 <210> 17 <211> 12 <212> PRT <213> Artificial Sequence <400> 17 Met Ala Leu Ala Val Arg Val Val Tyr Cys Gly Ala 1 5 10 <210> 18 <211> 12 <212> PRT <213> Artificial Sequence <400> 18 Lys Lys Asn Val Glu Ala Ile Gly Leu Leu Gly Gly 1 5 10 <210> 19 <211> 12 <212> PRT <213> Artificial Sequence <400> 19 Pro Pro Gly Pro Pro Leu Ser Ser Pro Arg Pro Arg 1 5 10 <210> 20 <211> 12 <212> PRT <213> Artificial Sequence <400> 20 Thr Met Asn Asn Glu Glu Asp Leu Leu Arg Ser Leu 1 5 10 <210> twenty one <211> 12 <212> PRT <213> Artificial Sequence <400> twenty one Thr Met Glu Pro Pro Gly Gly Arg Gln Lys Lys Arg 1 5 10 <210> twenty two <211> 12 <212> PRT <213> Artificial Sequence <400> twenty two Gln Glu Arg Gly Pro Thr Trp Asp Lys Asn Leu Arg 1 5 10 <210> twenty three <211> 12 <212> PRT <213> Artificial Sequence <400> twenty three Gly Thr Met Ala Val Leu Arg Gln Arg Pro Gly Arg 1 5 10 <210> twenty four <211> 12 <212> PRT <213> Artificial Sequence <400> twenty four Leu Cys Thr Arg Ser Trp Asp Val Thr Pro Asn Arg 1 5 10 <210> 25 <211> 12 <212> PRT <213> Artificial Sequence <400> 25 Ala Asn Gln Pro Ala Gln Cys Arg Lys Thr Arg Ile 1 5 10 <210> 26 <211> 12 <212> PRT <213> Artificial Sequence <400> 26 Glu Glu Ala Arg Leu Lys Tyr Asp Lys Ser Arg Ile 1 5 10 <210> 27 <211> 12 <212> PRT <213> Artificial Sequence <400> 27 Leu Asn Asp Gly Pro Lys Pro Gly Gln Ser Arg Phe 1 5 10 <210> 28 <211> 12 <212> PRT <213> Artificial Sequence <400> 28 Thr Ser Leu Tyr Lys Lys Val Gly Met Gly Arg Lys 1 5 10 <210> 29 <211> 12 <212> PRT <213> Artificial Sequence <400> 29 Tyr Lys Lys Val Gly Thr Met Arg Gly Arg Gly Leu 1 5 10 <210> 30 <211> 12 <212> PRT <213> Artificial Sequence <400> 30 Val Gly Thr Met Ala Ala Gly Arg Ala Pro Gly Lys 1 5 10 <210> 31 <211> 12 <212> PRT <213> Artificial Sequence <400> 31 Lys Lys Val Gly Thr Met Arg Gly Val Gly Tyr Pro 1 5 10 <210> 32 <211> 12 <212> PRT <213> Artificial Sequence <400> 32 Glu Gly Pro Leu Trp His Pro Arg Ile Cys Gly Ser 1 5 10 <210> 33 <211> 12 <212> PRT <213> Artificial Sequence <400> 33 Glu Met Ala Leu Ser Pro Pro Arg Ser Trp Gly Gln 1 5 10 <210> 34 <211> 12 <212> PRT <213> Artificial Sequence <400> 34 Arg Ser Gly Leu Arg Arg Arg Arg His Arg Gly Glu 1 5 10 <210> 35 <211> 12 <212> PRT <213> Artificial Sequence <400> 35 Val Ser Gly Ile Met Arg Arg Pro Trp Gly Met Asn 1 5 10 <210> 36 <211> 12 <212> PRT <213> Artificial Sequence <400> 36 Lys Arg Val Leu Ile Arg Val Thr Tyr Cys Gly Leu 1 5 10 <210> 37 <211> 12 <212> PRT <213> Artificial Sequence <400> 37 Met Ala Leu Ala Val Arg Val Val Tyr Cys Gly Ala 1 5 10 <210> 38 <211> 35 <212> PRT <213> Artificial Sequence <400> 38 Pro Ser Ser Pro Val Gln Thr Thr Pro Leu Ser Gln Ala Val Ala Thr 1 5 10 15 Pro Ser Arg Ser Ser Ala Ala Ala Ala Ala Ala Leu Asp Leu Ser Gly 20 25 30 Arg Arg Gly 35 <210> 39 <211> 36 <212> PRT <213> Artificial Sequence <400> 39 His His Gly Lys Gly Phe Phe Gly Ser Gly His Tyr Thr Ala Tyr Cys 1 5 10 15 Tyr Asn Thr Glu Gly Gly Ala Cys Ala Leu Leu Cys Gly Val Gly Asp 20 25 30 Thr Glu Arg Gly 35 <210> 40 <211> 35 <212> PRT <213> Artificial Sequence <400> 40 Val Ala Glu Ile Thr Lys Gln Leu Pro Pro Val Val Pro Val Ser Lys 1 5 10 15 Pro Gly Ala Leu Arg Arg Ser Leu Ser Arg Ser Met Ser Gln Glu Ala 20 25 30 Gln Arg Gly 35 <210> 41 <211> 10 <212> PRT <213> Artificial Sequence <400> 41 Lys Lys Arg Pro Pro Pro Gly Leu Asp Arg 1 5 10 <210> 42 <211> 10 <212> PRT <213> Artificial Sequence <400> 42 Ser Val Asn Ser Leu Leu Lys Glu Leu Arg 1 5 10 <210> 43 <211> 10 <212> PRT <213> Artificial Sequence <400> 43 His Glu Trp Val Leu Arg Glu Gly Glu Glu 1 5 10 <210> 44 <211> 10 <212> PRT <213> Artificial Sequence <400> 44 Glu Tyr Leu Leu Lys Met Ala Thr Glu Glu 1 5 10 <210> 45 <211> 10 <212> PRT <213> Artificial Sequence <400> 45 Glu Leu Cys Lys Ser Tyr Arg Arg Leu Gln 1 5 10 <210> 46 <211> 10 <212> PRT <213> Artificial Sequence <400> 46 Val Ala Leu Lys Phe Lys Pro Arg Lys His 1 5 10 <210> 47 <211> 10 <212> PRT <213> Artificial Sequence <400> 47 Gly Leu Gly Cys Lys Val Leu Arg Arg His 1 5 10 <210> 48 <211> 6 <212> PRT <213> Artificial Sequence <400> 48 Arg His Cys Gly Arg Thr 1 5 <210> 49 <211> 6 <212> PRT <213> Artificial Sequence <400> 49 Arg Ser His Gly Thr Leu 1 5 <210> 50 <211> 6 <212> PRT <213> Artificial Sequence <400> 50 Arg Phe Arg Gly Leu Arg 1 5 <210> 51 <211> 6 <212> PRT <213> Artificial Sequence <400> 51 Arg Asn Leu Gly Ile Arg 1 5 <210> 52 <211> 10 <212> PRT <213> Artificial Sequence <400> 52 Arg Gly Arg Leu Thr Arg Asn Lys Gly Pro 1 5 10 <210> 53 <211> 10 <212> PRT <213> Artificial Sequence <400> 53 Ser Leu Phe Arg Lys Arg Asn Lys Gly Lys 1 5 10 <210> 54 <211> 10 <212> PRT <213> Artificial Sequence <400> 54 Arg Thr Ala Ala Ser Gly Arg Arg Trp Gly 1 5 10 <210> 55 <211> 10 <212> PRT <213> Artificial Sequence <400> 55 Gly Leu Leu Lys Arg Pro Cys Leu Arg Gly 1 5 10 <210> 56 <211> 10 <212> PRT <213> Artificial Sequence <400> 56 Gln Arg Lys Leu Gln Arg Thr Ser Arg Gly 1 5 10 <210> 57 <211> 10 <212> PRT <213> Artificial Sequence <400> 57 Pro Lys Ser Lys Val Cys Gln Gln Arg Gly 1 5 10 <210> 58 <211> 10 <212> PRT <213> Artificial Sequence <400> 58 Lys Arg Leu Leu Lys Gly Ser Gln Tyr Gly 1 5 10 <210> 59 <211> 12 <212> PRT <213> Artificial Sequence <400> 59 Pro His Lys Arg Leu Leu Lys Gly Ser Gln Tyr Gly 1 5 10 <210> 60 <211> 10 <212> PRT <213> Artificial Sequence <400> 60 Lys Glu Ser Asn Asp Cys Ser Cys Gly Gly 1 5 10 <210> 61 <211> 10 <212> PRT <213> Artificial Sequence <400> 61 Asp Cys Val Cys Arg Gly Ser Thr Gly Gly 1 5 10 <210> 62 <211> 10 <212> PRT <213> Artificial Sequence <400> 62 Val Ala Pro Arg Ser Arg Asp Glu Arg Gly 1 5 10 <210> 63 <211> 10 <212> PRT <213> Artificial Sequence <400> 63 Ala His Gln Leu Gln Ala Leu Arg Arg Gly 1 5 10 <210> 64 <211> 5 <212> PRT <213> Artificial Sequence <400> 64 Leu Thr Gly Lys Gly 1 5 <210> 65 <211> 6 <212> PRT <213> Artificial Sequence <400> 65 Tyr Tyr Cys Phe Phe Gly 1 5 <210> 66 <211> 5 <212> PRT <213> Artificial Sequence <400> 66 Leu Glu Lys Gly Gly 1 5 <210> 67 <211> 5 <212> PRT <213> Artificial Sequence <400> 67 Ala Ala His Lys Gly 1 5 <210> 68 <211> 5 <212> PRT <213> Artificial Sequence <400> 68 Ala Leu Arg Arg Gly 1 5 <210> 69 <211> 5 <212> PRT <213> Artificial Sequence <400> 69 Gly Gly Ser Gly Gly 1 5 <210> 70 <211> 5 <212> PRT <213> Artificial Sequence <400> 70 Arg Asp Glu Arg Gly 1 5 <210> 71 <211> 5 <212> PRT <213> Artificial Sequence <400> 71 Ser Arg Val Lys Gly 1 5 <210> 72 <211> 5 <212> PRT <213> Artificial Sequence <400> 72 Pro Ala Ser Gly Gly 1 5 <210> 73 <211> 5 <212> PRT <213> Artificial Sequence <400> 73 Ala Ile His Gly Gly 1 5 <210> 74 <211> 5 <212> PRT <213> Artificial Sequence <400> 74 Gly Ala Glu Ala Gly 1 5 <210> 75 <211> 5 <212> PRT <213> Artificial Sequence <400> 75 Gly Ser Thr Gly Gly 1 5 <210> 76 <211> 5 <212> PRT <213> Artificial Sequence <400> 76 Arg Gly Met Gly Gly 1 5 <210> 77 <211> 5 <212> PRT <213> Artificial Sequence <400> 77 Leu Val His Ala Gly 1 5 <210> 78 <211> 5 <212> PRT <213> Artificial Sequence <400> 78 Ser Leu Gln Thr Gly 1 5 <210> 79 <211> 5 <212> PRT <213> Artificial Sequence <400> 79 Pro Val Pro Gly Gly 1 5 <210> 80 <211> 5 <212> PRT <213> Artificial Sequence <400> 80 Asn Tyr Lys Ser Gly 1 5 <210> 81 <211> 5 <212> PRT <213> Artificial Sequence <400> 81 Pro Arg Lys Gln Gly 1 5 <210> 82 <211> 5 <212> PRT <213> Artificial Sequence <400> 82 Thr Pro Arg Gly Gly 1 5 <210> 83 <211> 5 <212> PRT <213> Artificial Sequence <400> 83 Gly Cys Ser Gly Gly 1 5 <210> 84 <211> 5 <212> PRT <213> Artificial Sequence <400> 84 Glu Ala Gln Arg Gly 1 5 <210> 85 <211> 5 <212> PRT <213> Artificial Sequence <400> 85 Gly Lys Ala Trp Gly 1 5 <210> 86 <211> 5 <212> PRT <213> Artificial Sequence <400> 86 Pro Ala Gly Gly Gly 1 5 <210> 87 <211> 5 <212> PRT <213> Artificial Sequence <400> 87 Val Val Leu Tyr Gly 1 5 <210> 88 <211> 5 <212> PRT <213> Artificial Sequence <400> 88 Leu Thr Leu Lys Gly 1 5 <210> 89 <211> 5 <212> PRT <213> Artificial Sequence <400> 89 Gly Phe Gln Ser Gly 1 5 <210> 90 <211> 5 <212> PRT <213> Artificial Sequence <400> 90 Arg Val Gln Trp Gly 1 5 <210> 91 <211> 38 <212> PRT <213> Artificial Sequence <400> 91 Ser Arg Thr Glu Gly Gln Phe Gly Thr Thr Gln Ser Asn Gly Thr Phe 1 5 10 15 Phe Asn Gly Ala Ser Pro Gly Thr Pro Pro Ala Pro Ser Gln His Gln 20 25 30 Gln Ser Leu Thr Ser Leu 35 <210> 92 <211> 53 <212> PRT <213> Artificial Sequence <400> 92 Tyr Arg Pro Ile Pro Phe Gln Pro Glu Gly Ala Gly Glu Gly Thr Asp 1 5 10 15 Glu Asp Lys Ser Asn Arg Ile Gly Asn Asn Gly Leu Arg Leu Asn Asp 20 25 30 Gly Asn Gly Asn Gly Gln Leu Ala Pro Ser Pro Thr Pro Gln Gly Thr 35 40 45 Glu Ala Val Arg Ala 50 <210> 93 <211> 37 <212> PRT <213> Artificial Sequence <400> 93 Arg Lys Phe Ser Asn Asn Pro Gln Pro Asn Ala Ile Ser Asn Gly Thr 1 5 10 15 Ser Thr Ser Glu Arg Pro Gly Glu Gly Ala Thr Gln Gly Ile Val Glu 20 25 30 Glu Glu Val Leu Gln 35 <210> 94 <211> 37 <212> PRT <213> Artificial Sequence <400> 94 Ile Arg Thr Glu Ser Ala Glu Glu Ala Glu Met Ala Ser Val Pro Asn 1 5 10 15 Gly Ser Pro Ser Trp His Pro Gly Ala Ser His Val Val Asn Gly Ala 20 25 30 Ala Gly His Ser Asn 35 <210> 95 <211> 37 <212> PRT <213> Artificial Sequence <400> 95 Trp His Glu Ile Glu Met Glu Ser Gly Glu Glu Ala Met Glu Pro Ala 1 5 10 15 Asn Glu Thr Gly Asn Thr Leu Asn Gly Ser Pro Ser Trp His Pro Ser 20 25 30 Pro Ser His Val Ile 35 <210> 96 <211> 37 <212> PRT <213> Artificial Sequence <400> 96 Asn Arg Thr Asp Phe Ala Gly Glu Glu Asp Glu Met Asp Gly Val Leu 1 5 10 15 Asn Gly Ser Pro Ser Trp His Ala Ala Thr Ser His Ile Val Asn Gly 20 25 30 Ala Thr Val His Gln 35 <210> 97 <211> 37 <212> PRT <213> Artificial Sequence <400> 97 Asn Arg Thr Asp Thr Ala Ala Glu Ala Glu Met Asp Ser Val Leu Asn 1 5 10 15 Gly Ser Pro Ser Trp His Pro Pro Ala Gly His Val Val Asn Gly Ala 20 25 30 Thr Val His Arg Ser 35 <210> 98 <211> 37 <212> PRT <213> Artificial Sequence <400> 98 Asn Arg Thr Asp Thr Ala Ala Glu Ala Glu Met Asp Ser Val Leu Asn 1 5 10 15 Gly Ser Pro Ser Trp His Pro Pro Ala Gly His Val Val Asn Gly Ala 20 25 30 Ala Val His Arg Ser 35 <210> 99 <211> 37 <212> PRT <213> Artificial Sequence <400> 99 Asn Arg Thr Glu Val Leu Glu Gly Ala Glu Ile Pro Ser Thr Val Asn 1 5 10 15 Gly Ser Pro Ser Trp His Pro Ala Asp Ser Arg Ala Val Ser Gly Ala 20 25 30 Thr Gly His Ser Ser 35 <210> 100 <211> 37 <212> PRT <213> Artificial Sequence <400> 100 Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Leu Pro Ser Thr Val Asn 1 5 10 15 Gly Ser Pro Ser Trp His Pro Ala Asp Ser Arg Ala Gly Ser Gly Ala 20 25 30 Thr Gly His Ser Ser 35 <210> 101 <211> 37 <212> PRT <213> Artificial Sequence <400> 101 Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Glu Arg Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala 20 25 30 Val Asn Gly Ala Thr 35 <210> 102 <211> 59 <212> PRT <213> Artificial Sequence <400> 102 Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Glu Val Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ser Trp Gln Leu Ala Asp Ser Pro Ala 20 25 30 Ile Asn Gly Ala Thr Gly His Ser Ser Ser Leu Asp Ala Arg Glu Val 35 40 45 Ile Pro Met Ala Ala Val Lys Gln Gln Ala Leu 50 55 <210> 103 <211> 37 <212> PRT <213> Artificial Sequence <400> 103 Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Asp Met Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Ala Ser Trp His Leu Ala Asp Ser Pro Ala 20 25 30 Val Asn Gly Ala Thr 35 <210> 104 <211> 37 <212> PRT <213> Artificial Sequence <400> 104 Asn Arg Thr Glu Ala Pro Glu Gly Thr Gly Pro Glu Met Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ala Trp His Pro Ala Asp Ser Pro Ala 20 25 30 Val Asn Gly Ala Thr 35 <210> 105 <211> 37 <212> PRT <213> Artificial Sequence <400> 105 Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Asp Met Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala 20 25 30 Val Asn Gly Ala Thr 35 <210> 106 <211> 37 <212> PRT <213> Artificial Sequence <400> 106 Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Glu Ala Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala 20 25 30 Val Asn Gly Ala Thr 35 <210> 107 <211> 37 <212> PRT <213> Artificial Sequence <400> 107 Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Glu Met Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Pro 20 25 30 Ala Asn Gly Ala Thr 35 <210> 108 <211> 37 <212> PRT <213> Artificial Sequence <400> 108 Asn Arg Thr Glu Ala Pro Glu Gly Thr Asp Ser Glu Met Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ala Trp His Leu Ala Asp Ser Pro Ala 20 25 30 Val Asn Gly Ala Thr 35 <210> 109 <211> 37 <212> PRT <213> Artificial Sequence <400> 109 Asn Arg Thr Glu Ala Pro Glu Gly Thr Asp Ser Glu Met Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Val 20 25 30 Val Asn Gly Ala Thr 35 <210> 110 <211> 37 <212> PRT <213> Artificial Sequence <400> 110 Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Glu Met Glu Thr Pro 1 5 10 15 Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala 20 25 30 Val Asn Gly Ala Thr 35 <210> 111 <211> 20 <212> PRT <213> Artificial Sequence <400> 111 Leu Glu Ala Gly Cys Lys Asn Phe Phe Pro Arg Ser Phe Thr Ser Cys 1 5 10 15 Gly Ser Leu Glu 20 <210> 112 <211> 7 <212> PRT <213> Artificial Sequence <400> 112 Glu Asn Leu Tyr Phe Gln Gly 1 5 <210> 113 <211> 7 <212> PRT <213> Artificial Sequence <400> 113 Glu Asn Leu Tyr Phe Gln Ser 1 5 <210> 114 <211> 7 <212> PRT <213> Artificial Sequence <400> 114 Glu Asn Leu Tyr Phe Gln Met 1 5 <210> 115 <211> 7 <212> PRT <213> Artificial Sequence <400> 115 Asp Asn Leu Tyr Phe Gln Gly 1 5 <210> 116 <211> 7 <212> PRT <213> Artificial Sequence <400> 116 Gly Asn Leu Tyr Phe Gln Gly 1 5 <210> 117 <211> 7 <212> PRT <213> Artificial Sequence <400> 117 Tyr Asn Leu Tyr Phe Gln Gly 1 5 <210> 118 <211> 7 <212> PRT <213> Artificial Sequence <400> 118 Met Asn Leu Tyr Phe Gln Gly 1 5 <210> 119 <211> 7 <212> PRT <213> Artificial Sequence <400> 119 Trp Asn Leu Tyr Phe Gln Gly 1 5 <210> 120 <211> 7 <212> PRT <213> Artificial Sequence <400> 120 Cys Asn Leu Tyr Phe Gln Gly 1 5 <210> 121 <211> 7 <212> PRT <213> Artificial Sequence <400> 121 Arg Asn Leu Tyr Phe Gln Gly 1 5 <210> 122 <211> 7 <212> PRT <213> Artificial Sequence <400> 122 Leu Asn Leu Tyr Phe Gln Gly 1 5 <210> 123 <211> 7 <212> PRT <213> Artificial Sequence <400> 123 Arg Asn Leu Tyr Phe Gln Ser 1 5 <210> 124 <211> 7 <212> PRT <213> Artificial Sequence <400> 124 Ala Asn Leu Tyr Phe Gln Gly 1 5 <210> 125 <211> 7 <212> PRT <213> Artificial Sequence <400> 125 Gln Asn Leu Ile Phe Gln Gly 1 5 <210> 126 <211> 7 <212> PRT <213> Artificial Sequence <400> 126 Arg Asn Leu Tyr Phe Gln Cys 1 5 <210> 127 <211> 7 <212> PRT <213> Artificial Sequence <400> 127 Glu Cys Leu Tyr His Gln Gly 1 5 <210> 128 <211> 7 <212> PRT <213> Artificial Sequence <400> 128 Glu Arg Leu Tyr Val Gln Met 1 5 <210> 129 <211> 7 <212> PRT <213> Artificial Sequence <400> 129 Glu Ser Glu Tyr Cys Gln Glu 1 5 <210> 130 <211> 7 <212> PRT <213> Artificial Sequence <400> 130 Glu Val Met Tyr Ser Gln Ala 1 5 <210> 131 <211> 7 <212> PRT <213> Artificial Sequence <400> 131 Glu Phe Leu Tyr Ile Gln Asp 1 5 <210> 132 <211> 7 <212> PRT <213> Artificial Sequence <400> 132 Glu Arg Gly Tyr Gly Gln Val 1 5 <210> 133 <211> 7 <212> PRT <213> Artificial Sequence <400> 133 Glu Val Trp Tyr Cys Gln Cys 1 5 <210> 134 <211> 7 <212> PRT <213> Artificial Sequence <400> 134 Glu Val Ala Tyr Gly Gln Lys 1 5 <210> 135 <211> 7 <212> PRT <213> Artificial Sequence <400> 135 Glu Ser Arg Tyr Val Gln Ser 1 5 <210> 136 <211> 7 <212> PRT <213> Artificial Sequence <400> 136 Glu Gly Glu Tyr Trp Gln Arg 1 5 <210> 137 <211> 7 <212> PRT <213> Artificial Sequence <400> 137 Glu Ser Asn Tyr Gly Gln Met 1 5 <210> 138 <211> 21 <212> PRT <213> Artificial Sequence <400> 138 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Ala Leu 1 5 10 15 Ala Pro Tyr Ile Pro 20 <210> 139 <211> 24 <212> PRT <213> Artificial Sequence <400> 139 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Asp Arg 1 5 10 15 His Asp Ser Gly Leu Asp Ser Met 20 <210> 140 <211> 55 <212> PRT <213> Artificial Sequence <400> 140 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Gly Gly Ser Ser 1 5 10 15 His Gly Phe Pro Pro Glu Val Glu Glu Gln Asp Asp Gly Thr Leu Pro 20 25 30 Met Ser Cys Ala Gln Glu Ser Gly Met Asp Arg His Pro Ala Ala Cys 35 40 45 Ala Ser Ala Arg Ile Asn Val 50 55 <210> 141 <211> 31 <212> PRT <213> Artificial Sequence <400> 141 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Glu Asn 1 5 10 15 Leu Tyr Phe Gln Ser Gly Ser Gly Ala Leu Ala Pro Tyr Ile Pro 20 25 30 <210> 142 <211> 34 <212> PRT <213> Artificial Sequence <400> 142 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Glu Asn 1 5 10 15 Leu Tyr Phe Gln Ser Gly Ser Gly Asp Arg His Asp Ser Gly Leu Asp 20 25 30 Ser Met <210> 143 <211> 65 <212> PRT <213> Artificial Sequence <400> 143 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Gly Gly Ser Glu 1 5 10 15 Asn Leu Tyr Phe Gln Ser Gly Ser Gly Ser His Gly Phe Pro Pro Glu 20 25 30 Val Glu Glu Gln Asp Asp Gly Thr Leu Pro Met Ser Cys Ala Gln Glu 35 40 45 Ser Gly Met Asp Arg His Pro Ala Ala Cys Ala Ser Ala Arg Ile Asn 50 55 60 Val 65 <210> 144 <211> 31 <212> PRT <213> Artificial Sequence <400> 144 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Ala Leu 1 5 10 15 Ala Pro Tyr Ile Pro Gly Ser Gly Ala Leu Ala Pro Tyr Ile Pro 20 25 30 <210> 145 <211> 34 <212> PRT <213> Artificial Sequence <400> 145 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Asp Arg 1 5 10 15 His Asp Ser Gly Leu Asp Ser Met Gly Ser Gly Ala Leu Ala Pro Tyr 20 25 30 Ile Pro <210> 146 <211> 75 <212> PRT <213> Artificial Sequence <400> 146 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Gly Gly Ser Glu 1 5 10 15 Asn Leu Tyr Phe Gln Ser Gly Ser Gly Ser His Gly Phe Pro Pro Glu 20 25 30 Val Glu Glu Gln Asp Asp Gly Thr Leu Pro Met Ser Cys Ala Gln Glu 35 40 45 Ser Gly Met Asp Arg His Pro Ala Ala Cys Ala Ser Ala Arg Ile Asn 50 55 60 Val Gly Ser Gly Ala Leu Ala Pro Tyr Ile Pro 65 70 75 <210> 147 <211> 41 <212> PRT <213> Artificial Sequence <400> 147 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Glu Asn 1 5 10 15 Leu Tyr Phe Gln Ser Gly Ser Gly Ala Leu Ala Pro Tyr Ile Pro Gly 20 25 30 Ser Gly Ala Leu Ala Pro Tyr Ile Pro 35 40 <210> 148 <211> 44 <212> PRT <213> Artificial Sequence <400> 148 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Glu Asn 1 5 10 15 Leu Tyr Phe Gln Ser Gly Ser Gly Asp Arg His Asp Ser Gly Leu Asp 20 25 30 Ser Met Gly Ser Gly Ala Leu Ala Pro Tyr Ile Pro 35 40 <210> 149 <211> 75 <212> PRT <213> Artificial Sequence <400> 149 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Gly Gly Ser Glu 1 5 10 15 Asn Leu Tyr Phe Gln Ser Gly Ser Gly Ser His Gly Phe Pro Pro Glu 20 25 30 Val Glu Glu Gln Asp Asp Gly Thr Leu Pro Met Ser Cys Ala Gln Glu 35 40 45 Ser Gly Met Asp Arg His Pro Ala Ala Cys Ala Ser Ala Arg Ile Asn 50 55 60 Val Gly Ser Gly Ala Leu Ala Pro Tyr Ile Pro 65 70 75 <210> 150 <211> 237 <212> PRT <213> Artificial Sequence <400> 150 Met Gly Glu Ser Leu Phe Lys Gly Pro Arg Asp Tyr Asn Pro Ile Ser 1 5 10 15 Ser Thr Ile Cys His Leu Thr Asn Glu Ser Asp Gly His Thr Thr Ser 20 25 30 Leu Tyr Gly Ile Gly Phe Gly Pro Phe Ile Ile Thr Asn Lys His Leu 35 40 45 Phe Arg Arg Asn Asn Gly Thr Leu Leu Val Gln Ser Leu His Gly Val 50 55 60 Phe Lys Val Lys Asn Thr Thr Thr Leu Gln Gln His Leu Ile Asp Gly 65 70 75 80 Arg Asp Met Ile Ile Ile Arg Met Pro Lys Asp Phe Pro Pro Phe Pro 85 90 95 Gln Lys Leu Lys Phe Arg Glu Pro Gln Arg Glu Glu Arg Ile Cys Leu 100 105 110 Val Thr Thr Asn Phe Gln Thr Lys Ser Met Ser Ser Met Val Ser Asp 115 120 125 Thr Ser Cys Thr Phe Pro Ser Ser Asp Gly Ile Phe Trp Lys His Trp 130 135 140 Ile Gln Thr Lys Asp Gly Gln Cys Gly Ser Pro Leu Val Ser Thr Arg 145 150 155 160 Asp Gly Phe Ile Val Gly Ile His Ser Ala Ser Asn Phe Thr Asn Thr 165 170 175 Asn Asn Tyr Phe Thr Ser Val Pro Lys Asn Phe Met Glu Leu Leu Thr 180 185 190 Asn Gln Glu Ala Gln Gln Trp Val Ser Gly Trp Arg Leu Asn Ala Asp 195 200 205 Ser Val Leu Trp Gly Gly His Lys Val Phe Met Val Lys Pro Glu Glu 210 215 220 Pro Phe Gln Pro Val Lys Glu Ala Thr Gln Leu Met Asn 225 230 235 <210> 151 <211> 20 <212> DNA <213> Artificial Sequence <400> 151 tcattacaaa caagcacttg 20 <210> 152 <211> 20 <212> DNA <213> Artificial Sequence <400> 152 taggcatgcg aataattatc 20 <210> 153 <211> 20 <212> DNA <213> Artificial Sequence <400> 153 ccacatcgct cagacaccat 20 <210> 154 <211> 26 <212> DNA <213> Artificial Sequence <400> 154 ggcaacaata tccactttac cagagt 26 <210> 155 <211> 63 <212> DNA <213> Artificial Sequence <400> 155 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagcattggc cccctacatt 60 cca 63 <210> 156 <211> 72 <212> DNA <213> Artificial Sequence <400> 156 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagatcgcca cgattcaggg 60 ctcgattcca tg 72 <210> 157 <211> 165 <212> DNA <213> Artificial Sequence <400> 157 ggttctggtg gtgagaatct gtacttccaa ggtggaggag gatccagcca tggcttcccg 60 ccggaggtgg aggagcagga tgatggcacg ctgcccatgt cttgtgccca ggagagcggg 120 atggaccgtc accctgcagc ctgtgcttct gctaggatca atgtg 165 <210> 158 <211> 93 <212> DNA <213> Artificial Sequence <400> 158 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagaaaacct ctattttcag 60 tcaggtagtg gtgcattggc cccctacatt cca 93 <210> 159 <211> 102 <212> DNA <213> Artificial Sequence <400> 159 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagaaaacct ctattttcag 60 tcaggtagtg gtgatcgcca cgattcaggg ctcgattcca tg 102 <210> 160 <211> 195 <212> DNA <213> Artificial Sequence <400> 160 60. ggttctggtg gtgagaatct gtacttccaa ggtggaggag gatccgaaaa cctctatttt cagtcaggta gtggtagcca tggcttcccg ccggaggtgg aggagcagga tgatggcacg 120 ctgcccatgt cttgtgccca ggagagcggg atggaccgtc accctgcagc ctgtgcttct 180 gctaggatca atgtg <210> 161 <211> 93 <212> DNA <213> Artificial Sequence <400> 161 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagcattggc cccctacatt ccaggtagtg gtgcccttgc accatatatc ccc 93 <210> 162 <211> 102 <212> DNA <213> Artificial Sequence <400> 162 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagatcgcca cgattcaggg ctcgattcca tgggatctgg agcattggcc ccctacattc ca <210> 163 <211> 195 <212> DNA <213> Artificial Sequence <400> 163 ggttctggtg gtgagaatct gtacttccaa ggtggaggag gatccagcca tggcttcccg 60 ccggaggtgg aggagcagga tgatggcacg ctgcccatgt cttgtgccca ggagagcggg 120 atggaccgtc accctgcagc ctgtgcttct gctaggatca atgtgggatc tggagcattg 180 gccccctaca ttcca 195 <210> 164 <211> 123 <212> DNA <213> Artificial Sequence <400> 164 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagaaaacct ctattttcag 60 tcaggtagtg gtgcattggc cccctacatt ccaggtagtg gtgcccttgc accatatatc 120 ccc 123 <210> 165 <211> 132 <212> DNA <213> Artificial Sequence <400> 165 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagaaaacct ctattttcag 60 tcaggtagtg gtgatcgcca cgattcaggg ctcgattcca tgggtagtgg tgcccttgca 120 ccatatatcc cc 132 <210> 166 <211> 225 <212> DNA <213> Artificial Sequence <400> 166 ggttctggtg gtgagaatct gtacttccaa ggtggaggag gatccgaaaa cctctatttt cagtcaggta gtggtagcca tggcttcccg ccggaggtgg aggagcagga tgatggcacg 120 ctgcccatgt cttgtgccca ggagagcggg atggaccgtc accctgcagc ctgtgcttct 180 gctaggatca atgtgggtag tggtgccctt gcaccatata tcccc 225 <210> 167 <211> 31 <212> PRT <213> Artificial Sequence <400> 167 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Ser Gly Ala Leu 1 5 10 15 Ala Pro Tyr Ile Pro Asp Arg His Asp Ser Gly Leu Asp Ser Met 20 25 30 <210> 168 <211> 65 <212> PRT <213> Artificial Sequence <400> 168 Gly Ser Gly Gly Glu Asn Leu Tyr Phe Gln Gly Gly Gly Gly Ser Ser 1 5 10 15 His Gly Phe Pro Pro Glu Val Glu Glu Gln Asp Asp Gly Thr Leu Pro 20 25 30 Met Ser Cys Ala Gln Glu Ser Gly Met Asp Arg His Pro Ala Ala Cys 35 40 45 Ala Ser Ala Arg Ile Asn Val Gly Ser Gly Ala Leu Ala Pro Tyr Ile 50 55 60 Pro 65 <210> 169 <211> 93 <212> DNA <213> Artificial Sequence <400> 169 ggttctggtg gtgagaatct gtacttccaa ggtggatctg gagcattggc cccctacatt 60 ccagatcgcc acgattcagg gctcgattcc atg 93 <210> 170 <211> 195 <212> DNA <213> Artificial Sequence <400> 170 ggttctggtg gtgagaatct gtacttccaa ggtggaggag gatccagcca tggcttcccg 60 ccggaggtgg aggagcagga tgatggcacg ctgcccatgt cttgtgccca ggagagcggg 120 atggaccgtc accctgcagc ctgtgcttct gctaggatca atgtgggatc tggagcattg 180 gccccctaca ttcca 195

Claims

1. A proteolytic targeting virus, wherein the virus contains one or more proteolytic targeting molecules that can be recognized by the ubiquitin-proteasome system at one or more different sites on one or more viral proteins, wherein the virus is an influenza virus, and the site is before the stop codon at the C-terminus of the viral protein; and the viral protein and the proteolytic targeting molecule are connected by one or more linkers, wherein one or more of the PA, PB1, PB2, and M1 proteins of the influenza virus contain the proteolytic targeting molecule and the linker, and a flexible connector is further included between the proteolytic targeting molecule and the linker, wherein the proteolytic targeting molecule, the linker, and the flexible connector have the following connection mode: flexible connector-linker-flexible connector-proteolytic targeting molecule; in, The flexible connector-connector-flexible connector-protein hydrolysis targeting molecule is selected from the amino acid sequences shown in any one of SEQ ID NO:138-139.

2. The protein hydrolysis targeting virus as described in claim 1, wherein, The virus in question is an influenza A, B, or C virus.

3. The protein hydrolysis targeting virus as described in claim 1, wherein, In the PA of influenza virus and Each PB2 contains one or more protein hydrolysis targeting molecules and linker chains; Both the PA and PB1 proteins of influenza virus contain one or more proteolytic targeting molecules and linker chains. Both the PB2 and PB1 proteins of the influenza virus contain one or more proteolytic targeting molecules and linker strands. The PA, PB2, and PB1 proteins of influenza virus each contain one or more proteolytic targeting molecules and linker chains. The PA, PB2, PB1, and M1 proteins of influenza virus each contain one or more proteolytic targeting molecules and linker chains. The PB2, PB1, and M1 proteins of influenza virus each contain one or more proteolytic targeting molecules and linker chains. Both the PB1 and M1 proteins of the influenza virus contain one or more proteolytic targeting molecules and linker strands. Both the PB2 and M1 proteins of the influenza virus contain one or more proteolytic targeting molecules and linker strands.

4. Encoding a nucleic acid molecule that targets a virus via protein hydrolysis as described in any one of claims 1-3.

5. A nucleic acid vector expressing the protein hydrolysis-targeting virus as described in any one of claims 1-3.

6. A method for preparing a protein hydrolysis-targeted virus as described in any one of claims 1-3, the method comprising the following steps: 1) Cell line construction: Construct cell lines that can stably express proteases that selectively cleave the linker strands of proteases targeting viruses; 2) Gene mutation: Using genetic engineering methods, a nucleotide sequence of the protein-coding hydrolysis target molecule and linker strand is introduced before the C-terminal stop codon in the identified viral protein gene coding region; 3) Construct an expression vector by operatively linking the coding nucleotide sequence of the viral protein after gene mutation obtained in step 2) to the vector to obtain the expression vector; 4) Using reverse genetics, the expression vector from step 3) was co-transfected with other expression vectors used for influenza virus rescue in a cell line constructed in step 1) that selectively cleaves the linker strand of the proteolytic target virus to obtain the proteolytic target virus. or The method includes the following steps: ① Gene mutation: Using genetic engineering methods, a nucleotide sequence encoding a protein hydrolysis target molecule and a linker strand is introduced before the C-terminal stop codon in the coding region of the identified viral protein gene; ② Construct an expression vector for the mutant sequence, and operatively link the encoding nucleotide sequence of the viral protein after gene mutation obtained in step ① to the vector to obtain the expression vector; ③ Construct an overexpression vector for a protease that selectively cleaves the linker strand of a virus that targets protein hydrolysis; ④ Using reverse genetics technology, the expression vector obtained in step ②, other expression vectors required for virus rescue, and the expression vector obtained in step ③ are co-transfected into host cells. The successfully transfected host cells are cultured in a culture medium to obtain the proteolytic targeted virus. The cell lines were selected from HEK293T and MDCK cell lines.

7. The method according to claim 6, further comprising, after step 4): 5) The protein hydrolysis-targeting virus is replicated in the cell line obtained in step 1) to produce the protein hydrolysis-targeting virus.

8. The method according to claim 6, wherein, In step 1), the cell line is a cell line deficient in the ubiquitin-proteasome system.

9. The method according to claim 6, wherein, The cell line is an E3 ligase knockout or knockdown cell line.

10. The method according to claim 6, wherein, In steps 3) and ②, the expression vector is a plasmid.

11. The method according to claim 6, wherein, A proteasome inhibitor is added during the preparation of the virus.

12. The method according to claim 11, wherein, The proteasome inhibitor is MG132, MG-341, or lactosin.

13. The method according to claim 7, wherein, The method further includes step 6): detection: determining whether the protein hydrolysis-targeting virus has been successfully modified by measuring the replication ability of the protein hydrolysis-targeting virus obtained in step 4) in the cell line obtained in step 1) and in unmodified normal host cells; wherein, the protein hydrolysis-targeting virus that replicates in the cell line obtained in step 1) and whose replication ability is reduced or cannot replicate in unmodified normal host cells is a successfully modified protein hydrolysis-targeting virus.

14. The method according to claim 13, further comprising step 8): In the successfully modified protein hydrolysis-targeting virus, repeat steps 2)-4) so ​​that protein hydrolysis-targeting molecules and linker chains are introduced onto multiple viral proteins of the protein hydrolysis-targeting virus; or introduce multiple protein hydrolysis-targeting molecules and linker chains onto any viral protein of the protein hydrolysis-targeting virus.

15. The method of claim 6, wherein the protein hydrolysis-targeting virus is a protein hydrolysis-targeting influenza virus, comprising the following steps: 1) Cell line construction: The tobacco plaque virus protease TEVp was stably transduced into mammalian cell lines to construct cell lines that can stably express tobacco plaque virus protease TEVp; 2) Gene mutation: Using genetic engineering methods, a nucleotide sequence encoding a protein hydrolysis target molecule and a linker strand is introduced before the C-terminal stop codon in the identified influenza virus protein gene coding region; 3) Plasmid construction: The coding nucleotide sequence of the viral protein obtained in step 2) is operatively ligated to the plasmid to obtain the coding plasmid; 4) Using reverse genetics, the plasmid from step 3) was co-transfected with the cell line that stably expressed TEVp in step 1) with other plasmids used for influenza virus rescue to obtain proteolytic targeted influenza virus.

16. The method of claim 15, further comprising: 5) The protein was hydrolyzed and targeted to produce influenza virus in a stable cell line that stably expressed TEVp.

17. The method according to claim 16, wherein, The method also includes step 6): Detection: The success of the modification of the protein hydrolysis-targeted influenza virus is determined by measuring the dependence of the protein hydrolysis-targeted influenza virus obtained in step 4) on TEVp and the dependence of the inactivation of its packaging products on the proteasome pathway.

18. The method according to claim 17, further comprising step 7): Using the successfully modified protein hydrolysis-targeted influenza virus vector, repeat steps 2)-4) to introduce protein hydrolysis-targeting molecules and linker chains onto multiple viral proteins of the protein hydrolysis-targeted influenza virus; or introduce multiple protein hydrolysis-targeting molecules and linker chains onto any viral protein of the protein hydrolysis-targeted influenza virus.

19. The method according to claim 18, further comprising: Step 8) Select the successfully modified candidate and purify the product; Step 9) Perform safety or immunogenicity tests on the protein hydrolysis-targeted influenza virus from Step 8). The safe influenza virus is the successfully modified influenza virus compared to the wild-type virus.

20. The method of claim 18, wherein, The success of the modification of the proteolytic targeted influenza virus was determined by measuring the dependence of the obtained proteolytic targeted influenza virus on TEVp and the dependence of the inactivation of its packaging products on the proteasome pathway; proteolytic targeted viruses that retain their dependence on TEVp even after long-term passage were considered successful modification candidates.

21. A method for preparing attenuated live virus, replication-incapable live virus, replication-controllable live virus, and for preparing vaccines and medicaments for the prevention and treatment of viral infections, the method comprising the step of preparing a protein-hydrolyzed targeted virus using any one of claims 1-3, or using the method of any one of claims 6-20.

22. A vaccine or pharmaceutical composition comprising the protein-hydrolyzed targeted virus of any one of claims 1-3.

23. The vaccine or pharmaceutical composition according to claim 22, wherein the vaccine is a live attenuated vaccine, a live attenuated vaccine, or a live attenuated vaccine with controllable replication.

24. A system for preparing a protein hydrolysis-targeted virus as described in any one of claims 1-3, the system comprising: Cell lines that stably express proteases that selectively cleave the linker strands of viruses targeted by proteolysis; The system further includes a nucleic acid vector expressing the proteolytic targeting virus as described in any one of claims 1-3; the cell line is selected from HEK293T cell line and MDCK cell line.

25. The system according to claim 24, wherein, The cell line is a cell line that stably expresses the tobacco plaque virus protease TEVp.

26. The system according to claim 25, wherein, The cell line is a cell line with a deficiency in the ubiquitin-proteasome system.

27. The system according to claim 26, wherein, The cell line is an E3 ligase knockout or knockdown cell line.

Citation Information

Patent Citations

  • A respiratory syncytial virus F2 protein subunit vaccine and its preparation method

    CN102294027A

  • Site-directed mutated influenza virus, and live vaccine, preparation method and application thereof

    CN106929482A

  • Constrained proteins and uses therefor

    WO2016011501A1

  • Degron fusion constructs and methods for controlling protein production

    US20180179509A1

  • Self-inactivating viral vector

    WO2018203049A1